

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

## VASP mediated actin dynamics activate and recruit a filopodia myosin

Ashley L. Arthur<sup>1</sup>, Amy Crawford<sup>1</sup>, Anne Houdusse<sup>2</sup> & Margaret A. Titus<sup>1\*</sup>

<sup>1</sup> Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN 55455

<sup>2</sup> Structural Motility, Institut Curie, Paris Université Sciences et Lettres, Sorbonne Université, CNRS UMR144, 75005 Paris

\* corresponding author

Margaret A. Titus  
Department of Genetics, Cell Biology, and Development  
6-160 Jackson Hall  
321 Church St SE  
University of Minnesota  
Minneapolis, MN 55455

E-mail: [titus004@umn.edu](mailto:titus004@umn.edu)  
Phone: 612-625-8498  
Fax: 612-625-4648

## Abstract

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

Filopodia are thin, actin-based structures that cells use to interact with their environments. Filopodia initiation requires a suite of conserved proteins but the mechanism remains poorly understood. The actin polymerase VASP and a MyTH-FERM (MF) myosin, DdMyo7 in amoeba, are essential for filopodia initiation. DdMyo7 is localized to dynamic regions of the actin-rich cortex. Analysis of VASP mutants and treatment of cells with anti-actin drugs shows that myosin recruitment and activation in *Dictyostelium* requires localized VASP-dependent actin polymerization. Targeting of DdMyo7 to the cortex alone is not sufficient for filopodia initiation; VASP activity is also required. The actin regulator locally produces a cortical actin network that activates myosin and together they shape the actin network to promote extension of parallel bundles of actin during filopodia formation. This work reveals how filopodia initiation requires close collaboration between an actin binding protein, the state of the actin cytoskeleton and MF myosin activity.

### Keywords

Filopodia, actin dynamics, VASP, MyTH4-FERM myosin

## 57 Introduction

58

59 The efficient and directed migration of cells depends on their ability to detect and respond to  
60 chemical signals and physical cues in the environment. Filopodia are dynamic, thin membrane  
61 projections supported by a parallel bundle of actin filaments. They detect extracellular cues and  
62 play roles in processes such as neuronal growth cone guidance, durotaxis, cell-cell junction  
63 formation during development and metastasis (Heckman and Plummer, 2013; Arjonen et al.,  
64 2011; Cao et al., 2014; Shibue et al., 2012; Gallop, 2020). Although most intensely studied in  
65 animal cells, filopodia are ubiquitous in moving cells and have been observed in various  
66 Rhizaria, including predatory vampire amoebae, Discoba, Apusozoa, Amoebozoa and Holozoa  
67 (Sebé-Pedrós et al., 2013; Cavalier-Smith and Chao, 2003; Hess et al., 2012; Hanousková et al.,  
68 2019; Yabuki et al., 2013). Filopodia formation is orchestrated by a conserved core set of  
69 proteins that drive the formation and extension of actin bundles. These include a Rho family  
70 GTPase (Rac1, Cdc42), an actin polymerase (VASP or formin), an actin cross-linker and a  
71 MyTH4-FERM Myosin (MF; **myosin tail homology 4, band 4.1, ezrin, radixin, moesin**) (Mattila  
72 et al., 2007; Sebé-Pedrós et al., 2013; Nobes and Hall, 1995; Tuxworth et al., 2001; Faix et al.,  
73 2009). MF myosin motors regulate the formation of filopodia and other parallel actin based  
74 structures (Weck et al., 2017). *Dictyostelium* amoebae null for DdMyo7 do not produce filopodia  
75 or any filopodia-like protrusions, and expression of Myo10 in various mammalian cell types  
76 induces filopodia formation, implicating these myosins in filopodia initiation (Bohil et al., 2006;  
77 Tuxworth et al., 2001; Sousa and Cheney, 2005). These MF myosins are strikingly localized to  
78 filopodia tips, yet their function during filopodia initiation remains poorly defined.

79

80 Filopodia protrude from cells as slender projections filled with parallel actin filaments. Actin  
81 polymerization aided by VASP or formin facilitates the formation of a critical bundle size of 15-  
82 20 filaments which overcomes membrane tension and extends outwards as the actin filaments  
83 are cross-linked together (Mattila and Lappalainen, 2008; Mogilner and Rubinstein, 2005). Two  
84 models have been proposed for how these parallel actin bundles are formed. In one case the  
85 branched actin network is reorganized into a parallel array by the polymerase and bundler

86 VASP (Svitkina et al., 2003; Yang and Svitkina, 2011). In an alternative model, a linear actin  
87 polymerase such as formin nucleates new filaments that are rapidly bundled together and grow  
88 perpendicular to the plasma membrane (Faix and Rottner, 2006). MF myosins are thought to act  
89 during initiation by cross-linking actin filaments, perhaps zipping them together as the motors  
90 walk up the filament towards the cortex (Ropars et al., 2016). Support for this model comes  
91 from the observation that forced dimers of motors can induce filopodia or filopodia-like  
92 protrusions in cells (Tokuo et al., 2007; Arthur et al., 2019; Masters and Buss, 2017; Liu et al.,  
93 2021). Myo10 has also been implicated in elongation by transporting VASP towards the tip of  
94 the growing filopodium to promote continued growth (Tokuo and Ikebe, 2004).

95

96 The mechanism by which MF myosins are recruited to filopodial initiation sites is not well-  
97 understood. These myosins are regulated by head-tail autoinhibition, with the myosin folded  
98 into a compact conformation whereby binding of the C-terminal MF domain to the motor  
99 domain inhibits its activity. Opening up of the myosin followed by dimerization is required for  
100 activation of the myosin (Umeki et al., 2011; Sakai et al., 2011; Yang et al., 2006; Arthur et al.,  
101 2019). Partner binding mediated by their MF domains can typically stabilize the open, activated  
102 form of these myosins as well as promote dimerization (Sakai et al., 2011; Arthur et al., 2019; Liu  
103 et al., 2021). The MyTH4-FERM (MF) domains in these myosins can indeed mediate interaction  
104 with partner proteins such as microtubules (Weber et al., 2004; Toyoshima and Nishida, 2007;  
105 Planelles-Herrero et al., 2016) and the cytoplasmic tails of adhesion and signaling receptors  
106 (Hirao et al., 1996; Hamada, 2000; Zhang et al., 2004; Zhu et al., 2007). Myo10 has a unique tail  
107 among MF myosins with PH domains that bind to PIP3 rich membranes, which facilitates  
108 autoinhibition release and subsequent dimerization via a coiled-coil domain (Umeki et al., 2011;  
109 Lu et al., 2012; Ropars et al., 2016). DdMyo7, like mammalian microvilli and stereocilia myosins  
110 Myo7 and Myo15, lacks PH domains and it is not clear if activation is regulated by the  
111 concentration of some partners, or additional cellular signals.

112

113 MF myosin and the actin regulators VASP and formin have been observed to coalesce into  
114 punctae during the initiation step that precedes extension (Young et al., 2018; Arthur et al., 2019;

115 Cheng and Mullins, 2020). The mechanism by which Myo7s are targeted to such sites is  
116 unknown, but the first step of this process is likely to be regulated via relief of autoinhibition.  
117 Characterization of filopodia formation in *Dictyostelium* allows for a systematic examination of  
118 how DdMyo7 is recruited to the cell cortex through identification of the essential features of this  
119 myosin. The mechanism of DdMyo7 recruitment to the cortex and its potential functional  
120 relationship with the actin polymerase and bundler VASP were investigated to gain new  
121 insights into motor activation and the early steps of filopodia formation.

122

## 123 **Results**

124

### 125 **The DdMyo7 motor restricts cortical localization of the tail**

126 Disruption of the *Dictyostelium myo7* gene encoding DdMyo7 results in a significant  
127 defect in filopodia formation that is rescued by expression of GFP-DdMyo7 (Figure 1A,  
128 Supplemental Figure 1A and (Tuxworth et al., 2001; Petersen et al., 2016)). Most strikingly  
129 localized to filopodia tips, DdMyo7 is also in the cytosol and localized to the leading edge of  
130 cells (Figure 1B, Supplemental Figure 1A). In the course of characterizing functionally  
131 important regions of DdMyo7, it was observed that the tail domain (aa 809 - end) is localized all  
132 around the cell periphery in contrast to the full-length myosin which is often restricted at one  
133 edge of the cell cortex, (Figure 1B; (Petersen et al., 2016; Arthur et al., 2019)). This was  
134 unexpected as the myosin tail region is largely regarded as playing a key, even determining,  
135 role in targeting myosins. DdMyo7-mCherry and GFP- tail were co-expressed in *Dictyostelium*  
136 cells and a line scan through the cell showed that while both are present at a region of the cell  
137 that is extending outwards and producing filopodia (i.e. the leading edge), the tail is also  
138 strongly enriched in the cell rear (Figure 1C, line from Figure 1B). The extent of co-localization  
139 of the full-length myosin with the tail domain was assessed using cytofluorograms. This  
140 method quantifies co-localization of two proteins by comparing the intensity of the two  
141 fluorescent signals on a pixel-wise basis for the entire image with  $r$  representing the correlation  
142 coefficient (Bolte and Cordelières, 2006). Quantification revealed significantly less correlation  
143 between DdMyo7 and the tail ( $r = 0.63$ ) than is seen for the two full-length myosins ( $r = 0.86$ ).  
144 Due to the transient polarity of vegetative cells, a second measure of distribution of DdMyo7 on  
145 the cortex was carried out. To quantify the localized enrichment of DdMyo7 without any bias  
146 for manually identifying the leading edge, the intensity all around the cortex of cells was  
147 measured using a high throughput automated image analysis FIJI macro, *Seven* (Petersen et al.,  
148 2016) (Figure 1E). Actin is typically enriched at the leading edge with high intensity at one edge  
149 and lower intensity elsewhere (Figure 1F, G). The standard deviation of intensities values  
150 around the periphery was calculated for each cell (as exemplified in Figure 1H). This analysis  
151 shows that actin (RFP-Lifeact) and GFP-DdMyo7 are localized asymmetrically with a high

152 standard deviation of cortical intensity (Figure 1F, G, I). In contrast, the tail appears uniformly  
153 localized around the periphery (Figure 1F, G) and has a lower average SD for the cortical  
154 intensity around the cell periphery (Figure 1I). Interestingly, a tail-less forced dimer of the  
155 motor (motor-FD; Figure 1A) that is capable of inducing filopodial protrusions (Arthur et al.,  
156 2019) is also localized asymmetrically with a high standard deviation of intensity (Figure 1F, I).  
157 Together, these data establish that restricted localization of full-length DdMyo7 is dependent on  
158 its motor domain.

159

### 160 **DdMyo7 is localized to dynamic cortical actin**

161 The apparent asymmetrical distribution of DdMyo7 to the leading edge (Figure 1F)  
162 suggested that the actin at the cortex has a role in the recruitment and localization of DdMyo7.  
163 DdMyo7 and actin appear to be colocalized at the leading edge in cells expressing both GFP-  
164 DdMyo7 and an actin marker (Lifeact) (Figure 2A). Linescans all around the periphery show  
165 that indeed there is strong correlation of Lifeact and DdMyo7 fluorescence around the cell  
166 periphery (Figure 2B, yellow line from 2A). Cytofluorogram analysis also revealed strong  
167 correlation of the DdMyo7 and actin fluorescence intensities (Figure 2C). A line scan taken  
168 perpendicular to an extending leading edge showed a steady accumulation of DdMyo7  
169 intensity at the same time as an increase in actin intensity (Figure 2D, E). DdMyo7 and actin  
170 normalized intensities during leading edge extension were measured for 10 independent cells  
171 and a spline fit shows a robust correlation with actin intensity (Figure 2F).

172

173 The dependence of DdMyo7 localization on actin polymerization at the cortex was tested by  
174 treating cells with actin modulating drugs. CytochalasinA (cytoA) binds to the fast-growing  
175 (barbed) end of actin filaments and blocks incorporation of actin monomers, capping and  
176 stabilizing filaments. LatrunculinA (latA) sequesters monomers and prevents actin filament  
177 growth, and CK-666 blocks the Arp2/3 complex and actin branching (Cooper, 1987; Coué et al.,  
178 1987; Nolen et al., 2009). Cells were incubated with each of these drugs and the impact on  
179 DdMyo7 cortical targeting was assessed by measuring the intensity ratio of DdMyo7 in a 0.8  $\mu\text{m}$   
180 band around the perimeter versus the cytoplasm (see Figure 1E). Control cells have a

181 cortex:cytoplasm ratio of about ~1.2, indicating an overall 20% enrichment of DdMyo7 on the  
182 cell cortex (Figure 2G, H; (Arthur et al., 2019)). Treatment of cells with either cytoA or latA  
183 reduced the ratio to ~ 1 indicating a total loss of cortical localization of DdMyo7 (Figure 2H).  
184 CK-666 also significantly reduced DdMyo7 cortical recruitment (Figure 2G, H). Consistent with  
185 the reduction or loss of polymerized actin and cortical DdMyo7, filopodia formation was  
186 significant reduced with these actin modulating drugs (Table 1). Cells were also treated with  
187 Jasplakinolide (Jasp) that promotes monomer nucleation and stabilizes ADP-Pi actin filaments  
188 (Merino et al., 2018). Jasp treatment had the opposite effect, resulting in increased recruitment  
189 of DdMyo7 to the cortex and increased filopodia formation (Figure 2G, H; Table 1). The  
190 changes in DdMyo7 localization are specific to treatments that alter actin dynamics. The  
191 addition of either PI3Kinase inhibitors or microtubule depolymerizing agents such as  
192 nocodazole do not disrupt DdMyo7 cortical targeting (Supplemental Figure 2A, B). Control  
193 cells were imaged expressing GFP-CRAC (PIP3 marker, (Parent et al., 1998)), or GFP-tubulin  
194 (Neujahr et al., 1998), (Supplemental Figure 2A). The microtubule disrupting compound  
195 nocodazole had no effect on DdMyo7 in spite of the presence of two MF domains with  
196 micromolar affinity for microtubules in the DdMyo7 tail (Planelles-Herrero et al., 2016). Thus,  
197 the region of dynamic actin at the cortex controls the cortical recruitment of DdMyo7.

198

### 199 **The role of VASP in DdMyo7 cortical recruitment.**

200 Filopodia initiation and extension is driven by regulators of actin polymerization such as  
201 VASP and formin ((Mattila and Lappalainen, 2008); Figure 3A,B). The actin  
202 bundler/polymerase DdVASP accumulates at the leading edge of cells and is important for  
203 filopodia formation (Han et al., 2002; Breitsprecher et al., 2008). Interestingly, the *Dictyostelium*  
204 *vasp* null mutant phenocopies the *myo7* null mutant - it lacks filopodia, has reduced adhesion  
205 and smaller cell size (Han et al., 2002; Tuxworth et al., 2001). This is of particular note as  
206 mammalian Myo10 and VASP are observed to co-transport to the tips of filopodia and co-  
207 immunoprecipitate, suggesting a role for Myo10 in the transport of VASP to filopodia tips to  
208 promote filopodia growth (Tokuo and Ikebe, 2004; Lin et al., 2013). There is currently no  
209 evidence that DdMyo7 and *Dictyostelium* VASP (DdVASP) interact with each other and co-



210 immunoprecipitation experiments in *Dictyostelium* failed to detect any interaction  
211 (Supplemental Figure 3A). Surprisingly, in spite of this lack of interaction, DdMyo7 fails to  
212 target efficiently to the cortex of *vasp*- cells (Figure 3C, D). In contrast, DdVASP localizes to the  
213 cortex regardless of the presence of DdMyo7 (Figure 3C, D).

214

215 Formins are localized to the leading edge of migrating cells and play an important role in  
216 filopodia formation (Schirenbeck et al., 2005; Pellegrin and Mellor, 2005; Yang et al., 2007).  
217 Formins promote actin polymerization by incorporating actin monomers at the barbed end of  
218 actin filaments and elongate parallel actin filaments (Breitsprecher and Goode, 2013; Mellor,  
219 2010). The *Dictyostelium* diaphanous related formin dDia2 makes significant contributions to  
220 filopodia formation and is required for normal filopodia length (Figure 3A, B; (Schirenbeck et  
221 al., 2005)). Formin activity is not required for cortical recruitment of DdMyo7 as it is found to  
222 localize normally to the cortex of *dDia2* null (Figure 3C, D). These data reveal that DdVASP or  
223 its actin polymerization activity is critical for DdMyo7 recruitment and suggests that this  
224 bundler/polymerase acts upstream of DdMyo7.

225

### 226 **Selective recruitment of DdMyo7 requires specific actin polymerization factors**

227 The finding that DdVASP is critical for DdMyo7 cortical targeting raises the question of how  
228 it is acting to recruit this myosin. One simple explanation is that DdMyo7 is targeting to regions  
229 of the cell cortex where dynamic actin polymerization occurs. This hypothesis was tested by  
230 examining if robust recruitment of DdMyo7 could occur in the absence of DdVASP when actin  
231 polymerization was stimulated using different manipulations. Treatment of *Dictyostelium* with  
232 LatA treatment followed by washout produces robust actin waves (Gerisch et al., 2004). These  
233 waves are made of a dense Arp2/3 branched actin meshwork and class I myosins (MyoB,  
234 MyoC) (Jasnin et al., 2019; Brzeska et al., 2020). Cells expressing both RFP-LimE (a marker for  
235 F-actin) and GFP-DdMyo7 were induced to form waves that are readily apparent as broad  
236 circles of actin that emanate outwards towards the cell periphery. Actin waves were generated  
237 in either control or *vasp* null cells and in all cells visualized (n=6 per genotype) all waves are  
238 completely devoid of DdMyo7 (Figure 4A). Next, *vasp*- cells were treated with Jasp to stimulate

239 actin polymerization (Supplemental Figure 4A). No increase in cortical targeting of DdMyo7  
240 was observed in *vasp* nulls treated with Jasp when compared to untreated cells (Figure 4B, E).  
241 Blocking capping protein by overexpressing the capping protein inhibitor V-1 stimulates  
242 filopodia formation in *Dictyostelium* (Supplemental Figure 4B, (Jung et al., 2016)). V-1 also  
243 stimulates cortical actin network formation in *vasp* null *Dictyostelium* (Figure 4C). No increase  
244 in targeting was observed in *vasp* nulls with induced overexpression of V-1 (Figure 4B, D), nor  
245 was filopodia formation restored (Figure 4F).

246  
247         Activation of formins can also result in robust actin polymerization. These polymerases  
248 are tightly controlled by autoinhibition with the conserved DAD domain binding to the N-  
249 terminal DID domain, blocking actin nucleation activity. Mutation of conserved basic residues  
250 in the C-terminal DAD domain creates a constitutively activated (CA) formin (Wallar et al.,  
251 2006). A pair of charged residues are present in the dDia2 DAD domain and these were  
252 mutated - R1035A, R1036A - to create a CA formin (see alignment in Supplemental Figure 4C).  
253 Either dDia2 or dDia2-CA overexpressing *vasp* null cells exhibit restored and increased  
254 DdMyo7 cortical targeting (Figure 4B, E). Overexpression of dDia2-CA also promoted a modest  
255 rescue of filopodia formation (Figure 4F; Table 2). Linescans of cells stained with phalloidin  
256 show that while *vasp* nulls have less cortical F-actin than wild type cells, expression of dDia2-  
257 CA in *vasp* nulls resulted in increased cortical F-actin (Figure 4D). In summary, stimulation of  
258 actin polymerization by inducing actin waves, treating cells with Jasp, or blocking capping  
259 protein is not sufficient to promote DdMyo7 cortical recruitment in *vasp* null cells. In contrast,  
260 expression of activated formin is sufficient for cortical recruitment in *vasp* null cells. This  
261 strongly suggests that DdMyo7 cortical targeting specifically requires the activity of actin  
262 regulators that generate parallel actin filaments.

263

#### 264 **Mechanism of VASP mediated actin polymerization required for DdMyo7 recruitment**

265         The properties of VASP critical for DdMyo7 recruitment were investigated using separation  
266 of function mutations. VASP accelerates the rate of actin polymerization, bundles actin  
267 filaments and blocks capping protein from binding to the plus ends of actin filaments

268 (Breitsprecher et al., 2008, 2011; Hansen and Mullins, 2010). VASP is a constitutive tetramer that  
269 can bundle actin by binding to the sides of filaments (see Figure 5A; (Bachmann et al., 1999;  
270 Breitsprecher et al., 2008; Brühmann et al., 2017). DdVASP F-actin binding is mediated by a  
271 region within the EVH2 domain (aa 264-289) and tetramerization by a region at the C-terminus  
272 (aa 341-375) (Schirenbeck et al., 2006; Breitsprecher et al., 2008). Two different mutants were  
273 used to test if the VASP bundling activity is required for DdMyo7 recruitment (Figure 5D). A  
274 monomeric VASP was created by deleting the tetramerization domain (1M;  $\Delta$ 341-375) and an  
275 F-actin binding mutant was generated in which conserved lysines were mutated to glutamate  
276 (FAB K-E; KR275,276EE + K278E + K280E; based on (Hansen and Mullins, 2010)). The FAB K-E  
277 mutations are predicted to slow but not eliminate actin polymerization (Breitsprecher et al.,  
278 2008; Schirenbeck et al., 2006; Applewhite et al., 2007; Hansen and Mullins, 2010). Co-  
279 expression of either DdVASP-1M or DdVASP-FAB K-E with DdMyo7 in *vasp* null cells cannot  
280 fully restore DdMyo7 cortical recruitment (Figure 5B, E). The monomeric VASP-1M mutant  
281 partially rescues filopodia formation while the FAB K-E mutant does not (Figure 5C). The  
282 residual filopodia forming activity of the VASP-1M monomer could be attributed to its  
283 remaining anti-capping activity that is lost in the F-actin binding mutant (Breitsprecher et al.,  
284 2008; Hansen and Mullins, 2010). Both mutants are predicted to lack any bundling activity and  
285 show decreased recruitment of DdMyo7 to the cortex. These data indicate that bundling linear  
286 F-actin at the membrane could promote DdMyo7 targeting.

287

### 288 **Release of DdMyo7 autoinhibition dictates the spatial restriction of its recruitment**

289 DdMyo7 is enriched at the leading edge of cells, in contrast to the tail alone that localizes all  
290 around the cortex (Figure 1F, I). This difference suggests that head-tail autoinhibition restricts  
291 DdMyo7 localization. DdVASP is required for cortical localization but the lack of interaction  
292 between DdMyo7 and DdVASP suggests an indirect role. Furthermore, the GFP-DdMyo7 tail  
293 domain in *vasp* null cells targets to the cortex efficiently (Figure 6A-C). This confirms that direct  
294 DdMyo7 tail - DdVASP binding is not required for localization. Together these results  
295 suggested that VASP mediated actin networks release autoinhibition of DdMyo7. If so, then loss  
296 of autoinhibition regulation of DdMyo7 should eliminate the requirement of VASP for DdMyo7

297 to target to the cortex. To test this, two highly conserved charged residues at the extreme C-  
298 terminus of DdMyo7 (K2333, K2336) essential for head-tail autoinhibition were mutated (Yang  
299 et al., 2009; Petersen et al., 2016). Overexpression of this constitutively active mutant (DdMyo7-  
300 KKAA) stimulates filopodia formation and increases cortical localization in wild type cells  
301 (Table 2, (Petersen et al., 2016; Arthur et al., 2019)). DdMyo7-KKAA was expressed in *vasp* null  
302 cells where it targets to the cortex (Figure 6A-B). The cortical targeting of DdMyo7-KKAA in  
303 *vasp* nulls is not as robust as seen in control cells (Figure 6C), and it is localized more uniformly  
304 around the cortex in *vasp* nulls (less enriched in the leading edge or pseudopod) compared to  
305 controls (Figure 6E). These observations are consistent VASP activity contributing to shift the  
306 equilibrium of the autoinhibited myosin to the open, active state, recruiting the activated  
307 DdMyo7 to the cortex.

308

### 309 **VASP and cortical DdMyo7 are both required for filopodia formation**

310 The finding that loss of head-tail autoinhibition restores cortical recruitment of DdMyo7  
311 raised the question of whether an autoactivated motor is sufficient to rescue the filopodia  
312 formation defect seen in the *vasp* null cells. Expression of DdMyo7-KKAA in *vasp* nulls did not  
313 rescue their filopodia formation defect (Figure 6D), indicating that a specific DdVASP activity is  
314 required for filopodia initiation. The requirement for both cortical DdVASP and DdMyo7 for  
315 filopodia formation was further tested by targeting of the myosin to the cortex or membrane by  
316 fusing a prenylation sequence to its C-terminus (DdMyo7-CAAX, adapted from (Weeks et al.,  
317 1987)). DdMyo7-CAAX was robustly localized to the cortex in *myo7* null, wild type and *vasp*  
318 null cells (Fig. 6A, B; Table 2). Expression of DdMyo7-CAAX in wildtype or *myo7* nulls cells  
319 significantly stimulated filopodia formation (Figure 6A, D, Table 2). However, filopodia are not  
320 formed when DdMyo7-CAAX was expressed in *vasp* null cells (Figure 6A, D). These results  
321 establish that targeting DdMyo7 to the membrane alone is not sufficient for filopodia initiation  
322 and that DdVASP must also be present.

323

### 324 **Role of myosin motor activity in targeting and filopodia formation**

325 The data suggest that activation of autoinhibited DdMyo7 is promoted at the front of the cell  
326 in regions rich in newly polymerized F-actin. Actin binding by myosin involves conformational  
327 changes in the myosin head (Houdusse and Sweeney, 2016) and could destabilize the  
328 interactions between the motor head and the tail. To test this, two DdMyo7 mutants were  
329 designed, each with mutations in highly conserved connectors of the motor domain. Their  
330 functions are established by studies performed on the highly conserved motor domain DdMyo2  
331 (Sasaki et al., 2003; Friedman et al., 1998). The non-hydrolyzer mutant (E386V) binds ATP but  
332 cannot hydrolyze it, and thus stays in weak actin binding state, while the uncoupler mutant  
333 (I426A) can undergo conformational changes allowing strong interactions with F-actin but these  
334 conformational changes are not transmitted to the lever arm to produce force (illustrated in  
335 Figure 7A).

336  
337 The non-hydrolyzer (E386V) has a mutated glutamate in Switch II that is required to assist  
338 hydrolysis (Supplemental Figure 5A, (Friedman et al., 1998)). The non-hydrolyzer failed to  
339 efficiently cosediment with the actin cytoskeleton upon centrifugation (Figure 7D,  
340 Supplemental Figure 5B) indicating that it was indeed a weak actin binding mutant. The  
341 DdMyo7-E386V mutant does not target efficiently to the cell periphery (Figure 7B, E) or rescue  
342 filopodia formation (Figure 7F; Table 2). The lack of cortical localization by the non-hydrolyzer  
343 suggests that the tail remains bound to the motor, favoring an autoinhibited conformation, and  
344 is not free to bind to the cortex (see Figure 7A). To test this, the autoinhibition point mutations  
345 (KKAA) were introduced into the non-hydrolyzer to disrupt the head/tail interface. Blocking  
346 autoinhibition (KKAA) in the non-hydrolysis mutant (DdMyo7-E386A + KKAA) strikingly  
347 restores cortical targeting (Figure 7B, E; Table 2) but not filopodia formation (Figure 7F; Table  
348 2).

349  
350 A second motor mutation, I426A, resides in the relay helix and disrupts the interface with the  
351 converter that is critical to direct the swing of the lever arm during force generation. This  
352 mutant uncouples ATP hydrolysis from force generation (Supplemental Figure 5A, (Sasaki et  
353 al., 2003)). Thus, the uncoupler (DdMyo7-I426A) undergoes actin-activated ATP hydrolysis,

354 likely due to conformational changes directed from binding to actin, but it cannot exert force  
355 (illustrated in Figure 7A). DdMyo7-I426A cortical targeting is similar to what is seen for wild  
356 type DdMyo7 (Figure 7B, E). This indicates that actin binding destabilizes the autoinhibited  
357 form in this mutant. DdMyo7-I426A fails to efficiently rescue the filopodia formation defect of  
358 *myo7* null cells despite its targeting to the cortex (Figure 7F and Table 2), establishing that force  
359 generation by DdMyo7 is essential for filopodia initiation.

360

361 The uncoupler mutant motor is predicted to have normal actin binding and indeed its  
362 cortical asymmetry is similar to wildtype DdMyo7 (Figure 7B, C). In contrast, the motor of the  
363 non-hydrolyzer DdMyo7-E386A + KKAA mutant has weak actin binding so interaction with the  
364 cortex would be directed by the tail. As predicted, the DdMyo7-E386A + KKAA mutant is  
365 localized uniformly around the cortex (low cortical SD, Figure 7B, C). These observations  
366 provide support for the model that while the tail aids overall cortical localization, the motor-  
367 actin binding refines leading edge targeting of DdMyo7.

368

## 369 Discussion

370 Filopodia formation in amoeba requires both a MF myosin and VASP (Tuxworth et al., 2001;  
371 Han et al., 2002). The motor domain of the MF myosin DdMyo7, not the tail, targets it to actin-  
372 rich dynamic regions of the cortex where filopodia emerge (Figure 1). Actin network dynamics  
373 generated by DdVASP activity *in vivo* are important for myosin localization, promoting release  
374 of head-tail autoinhibition (Figure 6), freeing and activating the motor domain for binding to  
375 actin at the leading edge (Figures 1 and 7). This controlled activation of MF myosin leads to  
376 tuned activity at the right time and the right place to concentrate motors and facilitate filopodia  
377 formation, mainly from the leading edge of the cell. The role of DdVASP goes beyond simple  
378 recruitment of the motor since targeting of DdMyo7 at the membrane is not sufficient for  
379 filopodia initiation in *vasp* null cells (Figure 6A, D). Thus, both MF myosin and DdVASP  
380 together are needed to reorganize and polymerize actin at the cell cortex for filopodia to form  
381 (Figure 3 and 4). The data presented here support a model that first VASP activity, possibly  
382 bundling or polymerizing unbranched actin at the leading edge is upstream of DdMyo7  
383 activation (Figure 8A,B). DdMyo7 is activated by motor binding to a DdVASP generated actin  
384 network (Figure 8C), specifically the open state (Figure 8E) is stabilized by motor binding to the  
385 linear, bundles of actin resulting from DdVASP activity. Together, DdVASP and DdMyo7 drive  
386 filopodia initiation by further bundling and polymerizing actin (Figure 8D).

387

### 388 The role of DdVASP in myosin recruitment

389 Disruption of the dynamic actin network at the cortex that occurs by loss of *vasp* (Figure 3B,  
390 Figure 4D) or by treatment with anti-actin drugs such as cytoA or latA (Figure 2G, H) results in  
391 loss of cortical localization of DdMyo7. *Dictyostelium* VASP is a potent actin polymerase, its  
392 activity speeds actin elongation, bundles filaments and blocks capping proteins from binding to  
393 the growing ends of actin filaments (Breitsprecher et al., 2008). Both its actin polymerization  
394 and bundling activities could be important for DdMyo7 recruitment (Figure 5). In the absence  
395 of DdVASP, increased cortical actin generated by the formin dDia2 can also recruit and activate  
396 DdMyo7 (Figure 4B - E). However, recruitment is not restored by other means of increasing  
397 actin polymerization, including generating actin waves, polymerizing actin with Jasp or

398 blocking capping protein by overexpression of V-1. Thus, DdVASP does not simply recruit  
399 DdMyo7 by generating new actin polymers, but rather it is the nature of the network that  
400 DdVASP builds, likely growing linear actin filaments that are bundled together in parallel, that  
401 is critical for activation of DdMyo7.

402

403 The actin cortex of *vasp* nulls is less dense than found for wild type cells as revealed by  
404 phalloidin staining, suggesting that a robust leading edge actin network collapses without  
405 VASP (Figure 4D). Interestingly, evidence for VASP-dependent changes in the cortical actin  
406 network has recently been shown in B16 melanoma cells (Damiano-Guercio et al., 2020). The  
407 cortical actin network is normally dense and with many filaments oriented perpendicular to the  
408 membrane but in the absence of VASP, the network is more disperse and actin filaments are  
409 oriented in shallower angles with respect to the membrane (Damiano-Guercio et al., 2020).  
410 Thus, the formation of a VASP-mediated actin network at the cortex is likely to be important in  
411 this context as well as in other cell types.

412

#### 413 **Actin-dependent release of autoinhibition and leading edge targeting**

414 The motor domain of DdMyo7 is responsible for localizing this myosin to the dynamic  
415 leading edge of the cell, not the tail (Figures 1 and 2). The motor is typically sequestered by  
416 head-tail autoinhibition, a widely used mechanism for controlling myosin activity and reducing  
417 unnecessary energy expenditure (Heissler and Sellers, 2016). Overcoming autoinhibition is thus  
418 essential for liberating the motor and allowing it to target DdMyo7 to the dynamic cortex.  
419 DdMyo7 head/tail autoinhibition is mediated by charged residues in the FERM domain, similar  
420 to fly myosin 7a, and this regulates both cortical targeting and filopodia number (Petersen et al.,  
421 2016; Arthur et al., 2019; Yang et al., 2009). Blocking autoinhibition results in enhanced cortical  
422 targeting and filopodia formation, and bypasses the loss of cortical targeting observed in the  
423 absence of DdVASP (Figure 6). Motor activity (i.e. ATP hydrolysis) and actin binding are  
424 needed to release autoinhibition and promote cortical recruitment of DdMyo7 (Figure 7). Weak  
425 actin binding, even in the absence of autoinhibition does not promote leading edge targeting. In  
426 contrast, a mutant that can bind actin but uncouples force generation from ATP hydrolysis is



427 localized similarly to wild type DdMyo7 (Figure 7A-C). The uniform localization of the tail all  
428 around the cortex suggests that while the tail provides general cortical targeting, an active  
429 motor refines where activation occurs via its specific recognition of a dynamic actin-rich leading  
430 edge of the cell that is generated by DdVASP activity. Thus, motor domain mediated binding to  
431 a specific actin network is a key way to restrict localization of DdMyo7 during filopodia  
432 formation.

433

#### 434 **Conserved and divergent models of filopodia myosin function**

435 The mechanism of autoinhibition via motor-tail stabilizing interactions has been conserved  
436 throughout the evolution of myosins (Umeki et al., 2011; Sakai et al., 2011; Yang et al., 2009;  
437 Petersen et al., 2016; Weck et al., 2017; Heissler and Sellers, 2016). Mechanisms to overcome  
438 autoinhibition likely developed to restrict the recruitment and activation of myosins in time and  
439 space, allowing cells to fine-tune their activity. Here it is shown that DdMyo7 autoinhibition is  
440 relieved where the myosin will act by the cortical actin network that is generated by DdVASP.  
441 While this differs from the PIP3-mediated recruitment of metazoan Myo10, once activated these  
442 two evolutionarily distant filopodia myosins use similar mechanisms to generate filopodia.  
443 They both dimerize upon recruitment to the actin-rich cortex (Arthur et al., 2019; Lu et al., 2012)  
444 where they likely contribute to the reorganization of the Arp2/3 branched actin network to  
445 orient actin filaments perpendicular to the membrane (Svitkina et al., 2003; Tuxworth et al.,  
446 2001; Berg and Cheney, 2002; Tokuo et al., 2007; Arthur et al., 2019). Interestingly, both  
447 DdMyo7 and Myo10 work in cooperation with VASP, although they appear to do so in different  
448 ways. In the case of Myo10, it is seen to co-transport with VASP along the length of filopodia  
449 during extension and co-immunoprecipitate with VASP, although it is not known if the two  
450 proteins interact directly in vivo (Tokuo and Ikebe, 2004; Kerber et al., 2009; Lin et al., 2013). In  
451 contrast, the activity of DdVASP generates an actin-rich leading edge that recruits and activates  
452 DdMyo7 and there is no evidence that the two proteins interact with each other at present  
453 (Figures 1, 3 and 6; Supplementary Figure 3).

454

455 *Dictyostelium* are highly motile cells with dynamic, loosely bundled, short lived filopodia  
456 (Medalia et al., 2007). Given the early origins of Amoebozoa, a simple mechanism of coupling  
457 motor activation to actin dynamics at the pseudopod suggests that amoeboid filopodia  
458 formation is driven by a minimal regulatory circuit. It is tempting to speculate that VASP-  
459 dependent recruitment of an MF myosin represents an early form of cooperation between these  
460 two proteins. Perhaps as filopodia played wider roles in development and migration as  
461 multicellularity evolved, a signaling-based mechanism of MF myosin recruitment emerged with  
462 PIP3 binding to the three PH domain motif of Myo10 that replaced the first MF domain in  
463 present in other MF myosins. Thus, once Myo10 activation became dependent on PIP3, its  
464 motor activity was then used to promote VASP transport and filopodia extension. The  
465 evolution of the functional relationship between VASP and MF myosin would be interesting to  
466 explore in organisms such as *Drosophila* that make filopodia but lack Myo10 (*Drosophila* instead  
467 have a Myo22 with two MF domains like DdMyo7) and in the earliest organisms that have  
468 Myo7, Myo22 and Myo10 such as the filasterean *Capsaspora* and choanoflagellate *Salpingoeca*  
469 (Kollmar and Mühlhausen, 2017). It is possible that VASP plays a role in the recruitment of  
470 Myo10 to initiation sites or its activation in some systems, but this remains to be determined.  
471 The development of genetic tools in several evolutionarily significant organisms such as  
472 *Capsaspora* and *Salpingoeca* (Parra-Acero et al., 2018; Booth et al., 2018; Booth and King, 2020),  
473 unicellular organisms at the onset of multicellularity, should now allow for the study of the  
474 evolution of the VASP-filopodial MF myosin relationship in the targeting and activation of  
475 filopodial myosins.

476

477

## 478 **Materials and Methods**

### 479 **Cell lines, cell maintenance and transformations**

480 *Dictyostelium* control/wild-type (AX2 or AX3), *myo7* null (HTD17-1) (Tuxworth et al., 2001), *vasp*  
481 null (Han et al., 2002) and *dDia2* null (Schirenbeck et al., 2005) cells were cultured in HL5 media  
482 (Formedium). To create transgenic lines, cells were harvested, washed twice with ice cold H50  
483 (20 mM HEPES, pH 7.0, 50 mM KCl, 10 mM NaCl, 1 mM MgSO<sub>4</sub>, 5 mM NaHCO<sub>3</sub>, 1 mM  
484 NaH<sub>2</sub>PO<sub>4</sub> and flash spun at 10,000 X g until the rotor reached speed. Cells were resuspended at  
485 5e7 cells/mL and 100uL of cells was combined with 10µg DNA in a 0.1 cm gap cuvette. Cells  
486 were electroporated by pulsing twice, 5 seconds apart with a Bio-Rad Gene-Pulser set to 0.85  
487 kV, 25 µF, and 200 Ω. Cells were recovered 10 minutes on ice and plated in a 10cm dish for 24  
488 hours before moving to selection media, either 10µg/mL G418, 35µg/mL HygromycinB or both.  
489

490 Expression of the fusions proteins or null backgrounds was verified by western blotting  
491 using either anti-Myo7 (UMN87, (Tuxworth et al., 2005)), anti-GFP (Biolegend - B34) or anti-  
492 VASP (Breitsprecher et al., 2006) with anti-MyoB used as a loading control (Novak et al., 1995)  
493 (Supplemental Figure 6).  
494

### 495 **Generation of expression plasmids**

496 The GFP-DdMyo7 expression plasmid was created by fusing *gfp* to the 5' end of the *myoi*  
497 gene (dictyBase DDB: G0274455; (Titus, 1999) then cloning it into the pDXA backbone with the  
498 actin-15 promotor and a NeoR cassette as described (Tuxworth et al., 2001). Plasmids used for  
499 the expression of the full length tail (aa 809 - end) (Tuxworth et al., 2001), the KKAA  
500 autoinhibition mutant (K2333A/K2336A) (Petersen et al., 2016), motor forced dimer (aa 1-1020  
501 followed by the mouse Myo5A coiled coil region and a GCN4 leucine zipper) (Arthur et al.,  
502 2019) have been described previously. An expression clone for the full-length GFP-DdMyo7  
503 with a C-terminal prenylation site (CAAX) was generated using Q5 mutagenesis (New England  
504 Biolabs) to add codons encoding the CTLL\* prenylation motif from *Dictyostelium* RasG  
505 (UNIPROT: P15064) to the 3' end of the *myoi* gene. A DdMyo7-mCherry expression plasmid was  
506 generated by first TA cloning a PCR product (myo42 to myo185+2) encompassing the *myoi* 3'  
507 region of the gene (aa 475 - end) minus the stop codon using StrataClone (Agilent) (pDTi289+2).  
508 This fragment was then cloned into pDM CCherry, a modified pDM358 (Veltman et al., 2009)  
509 with the mCherry gene inserted for C-terminal fusions, generating pDTi299. The 5' end of *myoi*  
510 was then inserted by restriction cloning to create pDTi340. A motor mutant that cannot  
511 hydrolyze MgATP, the non-hydrolyzer E386V was designed based on a characterized  
512 *Dictyostelium* Myo2 mutant (Friedman et al., 1998). The combined non-hydrolyzer + KKAA was  
513 made by standard ligation cloning to introduce the motor domain sequence from the non-  
514 hydrolyzer mutant into KKAA full length expression plasmid by restriction enzyme digest with  
515 BsiWI and BstEII. The uncoupler mutant (I426A) was based on a characterized *Dictyostelium*  
516 Myo2 mutant (Sasaki et al., 2003) was cloned by Q5 mutagenesis. Fluorescent protein fusions of  
517 DdMyo7 were made using a combination of Q5 mutagenesis, Gibson assembly and restriction  
518 enzyme cloning. A DdMyo7-Scarlet I expression plasmid, pDTi517, was generated by first  
519 cloning a full-length *myoi* gene that has a BgIII site at the 5' end, lacks its internal BgIII site and

520 also its 3' stop codon, pDTi515+2, using a combination of Q5 mutagenesis, Gibson assembly and  
521 restriction enzyme cloning. The base Scarlet I-pDM304 expression plasmid for C-terminal  
522 fusions was generated by restriction enzyme cloning a codon-optimized synthesized Scarlet I  
523 gene (GenScript) into the extrachromosomal expression plasmid pDM304 (Veltman et al., 2009).  
524 The *myoi* gene was then cloned into mScarlet I-pDM304. Restriction cloning was used to create  
525 wild type and non-hydrolyzer mNeon DdMyo7 expression plasmids (pDTi516 and pDTi527,  
526 respectively). First, the base mNeon-pDM304 expression plasmid for N-terminal fusions was  
527 generated by restriction enzyme cloning a codon-optimized synthesized mNeon gene  
528 (GenScript) into the extrachromosomal expression plasmid pDM304 (Veltman et al., 2009).  
529 Then a full-length *myoi* gene that has a Bgl II site at the 5' end and lacks its internal Bgl II site  
530 was generated and cloned into either pDM448 (Veltman et al., 2009) for GFP-DdMyo7  
531 expression (pDTi492) or mNeon-pDM304 for mNeon-DdMyo7 expression (pDTi516).  
532 Restriction cloning was used to exchange the 5' region of the gene carrying the E386V mutation  
533 into the wild type pDTi516 expression plasmid, creating pDTi527. The dDia2-CA mutant was  
534 created by first PCR-amplifying the *forH* gene (using forH4L and forH8 oligos) from GFP-dDia2  
535 (Schirenbeck et al., 2005) then TA cloning the product using StrataClone (Agilent) to generate  
536 dDia2-SC. Mutations to generate a double R1035A, R1036A mutation were introduced dDia2-  
537 SC by Q5 mutagenesis (dDia2-CA SC). The wild type or mutant genes were restriction cloned  
538 into the extrachromosomal expression plasmid pDM449 (Veltman et al., 2009) to generate  
539 mRFPmars-dDia2 wt or CA. An inducible V-1 expression plasmid was created by first PCR-  
540 amplifying the *mtpn* gene with V-1 F and V-1 R oligos (dictyBase:DDB\_G0268038) using Ax2  
541 genomic DNA then TA cloning the product using StrataClone (Agilent) to generate V-1 SC. The  
542 V-1 insert was then restriction cloned into the extrachromosomal expression plasmid pDM334  
543 (Veltman et al., 2009) to generate GFP-inducible V-1. The sequence of all PCR generated clones  
544 was confirmed by Sanger sequencing (GeneWiz and University of Minnesota Genomics Center).  
545

546 The GFP-VASP expression plasmid was a gift from Dr. Richard Firtel (UCSD) (Han et al.,  
547 2002). The VASP tetramer and FAB, 1M mutants were not fused to GFP to avoid any steric  
548 hindrance with the fluorescent protein. The full-length VASP cDNA (dictyBase:DDB\_G0289541)  
549 was cloned into the pDM344 shuttle vector (Veltman et al., 2009) and the NgoM-IV fragment  
550 from this plasmid was ligated into pDM358-mApple that has the mApple gene (Shaner et al.,  
551 2008) cloned in between the *act6* promoter and *act15* terminator of pDM358 (Veltman et al.,  
552 2009). VASP-1M was created by introducing a SmaI site and stop codon into the *vasp* gene,  
553 altering the coding sequence from 334 PLSAPL to 334 PLSAPG\* using Q5 mutagenesis. The  
554 F-actin binding mutant (FAB K-E) was based on mutating previously identified critical F-actin  
555 binding residues (K275, R276, K278, and K280; (Schirenbeck et al., 2006) to glutamic acid  
556 (Hansen and Mullins, 2010) by Q5 mutagenesis. The sequence of all PCR generated clones was  
557 confirmed by Sanger sequencing (University of Minnesota Genomics Center). Oligonucleotides  
558 used are in the key resource table.

559

## 560 **Microscopy and imaging experiments**

561 **Live-cell imaging.** Microscopy of live cells was carried out as previously described (Petersen et  
562 al., 2016). Briefly, cells were adhered to glass bottom imaging dishes (CellVis, D35-10-1.5-N)

563 and starved for 45 to 75 min in nutrient-free buffer (SB, 16.8 mM phosphate, pH 6.4), and then  
564 imaged at 1 to 4 Hz on a spinning disk confocal (3i Marianas or Zeiss AxioObserver Z.1) with a  
565 63 X (1.4NA objective, 0.212 micron pixel size). The sample temperature was maintained at 19 -  
566 21°C. Samples were illuminated with 50mW lasers (488nm or 561nm), and a Yokogawa CSU-X1  
567 M1 spinning disk, and captured with an Evolve EMCCD camera. 4 - 6 Z sections of 0.28 - 0.5  
568 microns were taken with a 50 - 250ms exposure with 10-40% laser power. Cells were imaged for  
569 10 seconds – 10 minutes or longer depending on experiment. Cells are plated at a density of  
570  $5 \times 10^5$  per mL. Ten fields of view were collected from each imaging dish, with 2 - 20 cells per  
571 field of view. All data sets represent cells from at least three independent experiments and two  
572 independently transformed cell lines.

573

574 **Drug treatments.** Cells were washed free of media, adhered to glass bottom dishes and starved  
575 in nutrient-free buffer for 40 minutes. The buffer was replaced by buffer supplemented with the  
576 noted concentration of Jasplakinolide (diluted to 0.5% DMSO), cytochalasinA, latrunculin A,  
577 CK666, nocodazole, Ly294002, wortmannin or just DMSO alone. Jasplakinolide treatment was  
578 for 5 - 8 minutes, cells were incubated with all other compounds for 15 - 20 minutes, prior to  
579 imaging for 10 - 30 minutes. Additional drug concentration data are in Table 1. Cells expressing  
580 mApple-DdMyo7 and inducible GFP-V1 were induced overnight with 10 $\mu$ g/mL doxycycline  
581 (Sigma) to turn on expression of V-1 prior to imaging as above. Cells were treated with 0.25  
582  $\mu$ g/mL FM4-64 (Invitrogen) for 2 - 5 minutes to image filopodia with a membrane marker.

583

584 **LatrunculinA-induced actin waves.** Cells expressing GFP-DdMyo7 and the actin reporter RFP-  
585 LimE $\Delta$ coil (Gerisch et al., 2004) were induced to generate travelling actin waves using a  
586 modified protocol (Gerisch et al., 2004). Cells rinsed with 16mM phosphate buffer pH 6.4 were  
587 seeded on glass bottom dishes (Celvis) at  $5 \times 10^5$  cell/mL, incubated in phosphate buffer for 30  
588 minutes and then supplemented with 5 $\mu$ M latrunculinA for 20 minutes. The solution was  
589 diluted to 0.5 $\mu$ M latA and cells incubated for an additional 30 minutes, then imaged for up to 2  
590 hours. Images were captured in 5 - 10 0.3  $\mu$ m Z sections by spinning disk confocal microscopy  
591 (see above) every 5 seconds to make 10 - 30 minute movies.

592

593 **Actin intensity linescans.** Cells were seeded as above and fixed using picric acid (Humbel and  
594 Biegelmann, 1992). Cells were incubated with 568- or 647- Alexa phalloidin (Invitrogen) for 45  
595 minutes, rinsed with PBS-glycine, then water and mounted using prolong-diamond (Molecular  
596 Probes). Slides were imaged using a Nikon Widefield Eclipse NiE microscope with a 40X/1.3  
597 NA objective, CoolSNAP CCD camera and Sola light source. Maximum Z projections (5 - 10 0.3  
598  $\mu$ m) were analyzed by manually drawing a linescan perpendicular to the long axis and  
599 compiled with the FIJI/ImageJ macro and RStudio scripts (Zonderland et al., 2019).

600

## 601 **Data Analysis**

602 **Protein alignments.** Myosin motor domain sequences were aligned using T-coffee algorithm  
603 “Expresso” (Notredame et al., 2000). These included Uniprot sequence entries: P54697,  
604 Q9U1M8, P08799, P19524, K4JEU1, Q9V3Z6, Q9HD67, Q13402, Q6PIF6. Diaphanous related  
605 formins were aligned using Clustal Omega, using Uniprot entries: Q54N00, O70566, O60879,

606 P41832, P48608 and the DAD domain basic residue highlighted is based on (Wallar et al., 2006;  
607 Lammers et al., 2005). VASP mutations were made by first creating a structural alignment with  
608 DdVASP (Uniprot: Q5TJ65) and Human VASP (Uniprot: P50552) in T-coffee algorithm  
609 “Expresso”.

610

611 **Image Analysis.** Cortex to cell ratio, cortical asymmetry and filopodia per cell were quantified  
612 using a custom FIJI plugin “Seven” ((Petersen et al., 2016), code available on github linked to  
613 titus.umn.edu). Cells not expressing transgenic proteins were excluded from the analysis.  
614 Analysis was done on maximum intensity projections. First, the image is thresholded to mask  
615 the cell. This mask excludes the nucleus, which is devoid of DdMyo7 signal, and filopodia tips  
616 extended from the cell body. The cortical band (0.8 $\mu$ m) intensity, standard deviation of  
617 intensity in the cortical band was measured for each cell. Next, a radial tip search identifies  
618 filopodia and registers them to each cell to count the number of filopodia per cell. Extending  
619 pseudopodia and actin correlation were done in FIJI by reslicing through extending  
620 pseudopodia and making plot profiles of the edge of the cell. Intensity profiles were normalized  
621 between 0-1, and multiple cells were averaged by fitting a restricted cubic spline.

622 **Statistical analysis.** Statistics were calculated in Prism 8 (GraphPad). One-way ANOVA  
623 analysis with post hoc Tukey test or Dunnett’s multiple comparison to wild-type control was  
624 used to compare groups; Student’s t test was used when only comparing 2 datasets. Statistical  
625 tests were calculated on full datasets, experimental means are shown on graphs to demonstrate  
626 experimental variability. Automated analyses data points deemed definite outliers (0.1%) by  
627 Rout method were excluded for cortex:cytoplasm ratio. Error bars are SEM, unless noted.  
628 Significance differences are in comparison to control (DdMyo7), unless noted. Tables have  
629 filopodia number as average number of filopodia in cells with at least one filopod. SEM is  
630 standard error of the mean. Capitalized ‘N’ indicates number of experiments lowercase n is  
631 number of cells.

632 **Cytoskeleton Association.** Log phase cells expressing GFP-DdMyo7 were grown on  
633 bacteriological plastic plates (150 mm) were rinsed twice in PB then resuspended, counted and 5  
634  $\times 10^7$  cells collected by centrifugation (Beckman J6, 200  $\times$  g). The pellet was resuspended in 1 ml  
635 lysis buffer (100 mM Tris, pH 8.1, 5 mM MgCl<sub>2</sub>, 5 mM EDTA and 2.5 mM EGTA), washed once  
636 then lysed with Lysis Buffer + 1% Tx-100, 1 mM TLCK (Sigma), 1 mM TPCK (Sigma), 1X HALT  
637 protease inhibitor cocktail (Pierce ThermoFisher) at room temperature. The 0.5 ml sample was  
638 spun immediately at 20,000  $\times$  g, 4  $^{\circ}$ C for 20 min. The supernatant was collected and pellet  
639 resuspended and homogenized in 0.25 ml of lysis buffer. An equal volume of ULSB gel sample  
640 buffer was added to aliquots from the sup and pellet and the samples run on a 4 - 15% gradient  
641 TGX SDS PAGE gel (BioRad) then transferred to nitrocellulose (Licor). The blot was probed for  
642 the presence of DdMyo7 and actin followed by fluorescent secondary antibodies (LiCor) and  
643 then imaged with the LiCor Odyssey. Quantification of the DdMyo7 band was performed  
644 using Image Studio Lite (Licor).

645 **Key Resources**

646

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Software	Graphpad 8.0		Statistical Analysis	graph preparation, statistical analysis
Software	Seven	(Petersen et al., 2016)		filopodia counting, cortex:cell ratio
Antibody	Rabbit anti-DdMyo7	Tuxworth et al, 2005	UMN-87	1:2000
Antibody	mouse anti-GFP	Biologend	B34	1:5000
Antibody	Rabbit anti-vasp	(Breitsprecher et al., 2008)	Provided by Dr. Jan Faix (Hannover Med, Hannover Germany)	1:500
Antibody	Rabbit anti myoB	Novak et al., 1995		1:2000
Antibody	Rabbit anti-mCherry	Proteintech	26765-1-AP	1:500
Antibody	Goat anti rabbit	Licor	IR680	1:2500-1:10,000
Antibody	Goat anti mouse	Licor	IR800	1:2500-1:10,000
Antibody	Mouse anti-Dictyostelium actin	(Westphal et al., 1997)	Provided by Dr. Günther Gerisch (MPI Martinsried)	1:4000
Oligonucleotide	CAAX F		5' -ttattaTAAAAAATTTAAAATAAAATAAAATCTCGTG-3'	pDTi346
Oligonucleotide 5'->3'	CAAX R		5' -tgtacaTTGAGAAGAATAAAATTGATAAACTG-3'	pDTi346
Oligonucleotide 5'->3'	E386V F		5' -ttttgtAAATTTTAAAAAGAATAGTTTTGAACAATTTTG-3'	pDTi364

Oligonucleotide 5'->3'	E386V R		5' -ccaaagATATCCAATACACCAATAAATGTTG -3'	pDTi364
Oligonucleotide 5'->3'	I426A F		5' -AAAAGAAAAAgctAATTGGAGTAAGATCGTATATAATG -3'	pDTi435
Oligonucleotide 5'->3'	I426A R		5' -TCATATTCTTCTTGTCTAATTTAAAAATATG -3'	pDTi435
Oligonucleotide 5'->3'	myi42		5' -catgccatggcagcagcagcaACCTTAAAGAGAAAAGCACCCAGTCG -3'	pDTi289+2
Oligonucleotide 5'->3'	myi185+2		5' - gctagcaaTTGAGAAGAATAAAATTGATAAACTGAAGC - 3'	pDTi289+2
Oligonucleotide 5'->3'	VASP339* F		5' -taataaAGAGCATCTCAACATTAAGTAG-3'	pVASP29
Oligonucleotide 5'->3'	VASP339* R		5' -cccgggAGCTGATAAGGATGGTGAAG-3'	pVASP29
Oligonucleotide 5'->3'	FAB K-E F		5' -gaaatggagGCAGCAGCATCTCAACCAA-3'	pVASP34
Oligonucleotide 5'->3'	FAB K-E R		5' -ggcttcctcGGCCATAACTTCGGCCAT-3'	pVASP34
Oligonucleotide 5'->3'	forH4L F		5' -AATTGACCAGATCTAATTTGAG -3'	dDia2-SC
Oligonucleotide 5'->3'	forH8 R		5' -actagtTTATTTTTTAATTGGCCTGATGG - 3'	dDia2 SC
Oligonucleotide 5'->3'	forH9 F		5' -ggatccATGTCTTTTGATTTAGAGAGTAATAGTAGTGG -3'	dDia2-CA SC
Oligonucleotide 5'->3'	forH10 R		5' - ATTCAAAGATagaagaGTTGGTGATTCTGTCATTG -3'	dDia2-CA SC
Oligonucleotide 5'->3'	V1 F		5' - agatctATGGAAGAACAAAATGATTTAC - 3'	V-1 SC
Oligonucleotide 5'->3'	V1 R		5' - actagtTTATTTTAATAATGCTTTAATATCAGC - 3'	V-1 SC
Chemical	HL5 Medium			
Chemical	including Glucose	Formedium	HLG0103	
Chemical	G418	Fisher Scientific	BP-673	



Chemical	G418	Gold Biotechnology	G-418
Chemical	Hygromycin B	Gold Biotechnology	H-270
Chemical	Doxycycline Hyclate	Sigma	D9891
Chemical	Pencillin G Sodium Salt	Sigma	P3032
Chemical	Streptomycin Sulfate	Sigma	S9137
Chemical	Cytochalasin A	Sigma	C-6637
Chemical	Jasplakinolide	Sigma	J4580
Chemical	Latrunculin A	Sigma	L5163
Chemical	LY294002	EMD Millipore	440204
Chemical	Nocodazole	Sigma	M1404
Chemical	Wortmannin	Sigma	W1628
Chemical	CK666	(Nolen et al., 2009)	

Gift from Brad Nolen (U.  
Oregon)

647

648

649 synthesized DNA mScarlet I

650 actagtgggtgggttcaggagTTTTCAAAAGGTGAAGCCGTTATTAAAGAATTTATGAGATTCAAGGTTACATGGAAGGAAGTATGAACGGTCATGAATT  
651 TGAGATTGAAGGAGAAGGTGAAGGTAGACCATATGAAGGCACCCAAACAGCTAAATTTAAAAGTAACTAAAGGTGGTCCATTACCATTTAGTTGGGATA  
652 TTTTATCTCCACAATTTATGTATGGTTCACGTGCTTTCAttAAACATCCAGCAGATATTCCAGATTATTATAAAACAATCATTTCCAGAAGGTTTTAAA  
653 TGGGAACGTGTCATGAACTTTGAAGATGGTGGAGCAGTTACAGTCACACAAGATACCTCATTAGAAGATGGTACATTAATATATAAAGTTAAATTACG  
654 TGGTACTAATTTTTCCACCAGACGGTCCAGTAATGCAAAAAAAAAACAATGGGCTGGGAAGCTAGTACAGAACGTTTATATCCTGAAGATGGTGTCCCTTA  
655 AAGGCGATATAAAAAATGGCCTTGAGATTAAAGGATGGTGGTAGGTATTTAGCAGATTTCAAACCACTTATAAAGCAAAAAACCAGTTCAAATGCCA  
656 GGTGCATATAATGTTGATAGAAAACCTTGATATTACCAGTCATAATGAAGATTACACAGTTGTTCGAACAATACGAACGTTCTGAAGGTCGTCATAGCAC  
657 TGGTGGTATGGATGAATTATACAAATAAgctagc

658

659 synthesized DNA mNeon

660 ggatccATGGTGAGTAAAGGTGAAGAAGATAATATGGCATCGTTACCAGCTACACATGAGTTACATATATTCGGTAGCATTAAATGGTGTTGATTTGA  
661 TATGGTGGGACAAGGTACCGGTAATCCTAATGATGGTTACGAAGAACTAAATTTAAAATCGACTAAAGGTGACTTACAATTTTCTCCATGGATTTTAG  
662 TGCCACATATAGGGTATGGTTTTTCATCAATACTTACCATATCCAGATGGTATGTCACCATTTCAAGCTGCAATGGTTGATGGATCAGGTTATCAAGTT  
663 CATAGAACAATGCAATTTGAAGATGGTGCTTCATTAAGTTAATTATAGATACACATATGAAGGCTCACATATTAAAGGTGAAGCTCAAGTTAAAGG  
664 TACTGGTTTTCCAGCCGATGGCCCAGTTATGACAAATAGTTTTAACAGCAGCAGATTGGTGTAGATCCAAAAAACTTATCCAAATGATAAAACAATTA  
665 TTTCAACTTTTTAAATGGTCATATAACAACCGGTAATGGTAAACGTTATCGTTCAACAGCCCGTACAACATATACTTTTGCTAAACCAATGGCAGCTAAT  
666 TATTTAAAAAATCAACCAATGTATGTTTTTCGTAAAACAGAGTTAAAACATTCAAAAACAGAACTTAATTTTAAAGAATGGCAAAAAGCATTTACAGA  
667 CGTTATGGGTATGGATGAACTTTATAAGAgatct

## 668 **Acknowledgements**

669

670 We thank Livia Songster, Annika Schroder and Casey Eddington for many helpful discussions  
671 and assistance with experiments and analysis. We also thank Dr. Karl Petersen for the initial  
672 characterization of the motor mutations and for support with SEVEN. We are grateful to  
673 Professor Robert Insall (Beatson) for stimulating discussions, Dr. John Cooper (Washington U),  
674 Dr. Volodya Gelfand (Northwestern U), Dr. Lil Fritz-Laylin and members of the Fritz-Laylin lab  
675 (UMass Amherst) for helpful comments and critical reading of the manuscript. Thanks for Dr.  
676 Jan Faix (U Hannover) for providing the dDia2 nulls and VASP antibody and Dr Brad Nolen (U.  
677 Oregon) for supplying the CK666. Our thanks also to the University of Minnesota Imaging  
678 Center for additional imaging support. This work was supported by the CNRS, ANR-17-CE11-  
679 0029-01, and Ligue Contre le Cancer RS16 grants (A.H.). The A.H. team is part of the  
680 LabexCelTisPhyBio:11-LBX-0038, which is part of the Initiatives of Excellence of Université  
681 Paris Sciences et Lettres (ANR-10-IDEX-0001-02PSL) and the NIH National Institute of General  
682 Medical Sciences (F31GM128325 to A.L.A. and R01GM122917 to M.A.T.).

## 683 Literature Cited

684

685 Applewhite, D.A., M. Barzik, S. Kojima, T.M. Svitkina, F.B. Gertler, and G.G. Borisy. 2007.  
686 Ena/VASP proteins have an anti-capping independent function in filopodia formation.  
687 *Mol. Biol. Cell.* 18:2579–2591.

688 Arjonen, A., R. Kaukonen, and J. Ivaska. 2011. Filopodia and adhesion in cancer cell motility.  
689 *Cell Adhes. Migr.* 5:421–430.

690 Arthur, A.L., L.D. Songster, H. Sirkia, A. Bhattacharya, C. Kikuti, F.P. Borrega, A. Houdusse,  
691 and M.A. Titus. 2019. Optimized filopodia formation requires myosin tail domain  
692 cooperation. *Proc. Natl. Acad. Sci.* 116:22196–22204.

693 Bachmann, C., L. Fischer, U. Walter, and M. Reinhard. 1999. The EVH2 domain of the  
694 vasodilator-stimulated phosphoprotein mediates tetramerization, F-actin binding, and  
695 actin bundle formation. *J. Biol. Chem.* 274:23549–23557.

696 Berg, J.S., and R.E. Cheney. 2002. Myosin-X is an unconventional myosin that undergoes  
697 intrafilopodial motility. *Nat. Cell Biol.* 4:246–250.

698 Bohil, A.B., B.W. Robertson, and R.E. Cheney. 2006. Myosin-X is a molecular motor that  
699 functions in filopodia formation. *Proc. Natl. Acad. Sci.* 103:12411–12416.

700 Bolte, S., and F.P. Cordelières. 2006. A guided tour into subcellular colocalization analysis in  
701 light microscopy. *J. Microsc.* 224:213–232.

702 Booth, D.S., and N. King. 2020. Genome editing enables reverse genetics of multicellular  
703 development in the choanoflagellate *Salpingoeca rosetta*. *Elife.* 9:e56193.

704 Booth, D.S., H. Szmids-Middleton, and N. King. 2018. Transfection of choanoflagellates  
705 illuminates their cell biology and the ancestry of animal septins. *Mol. Biol. Cell.* 29:3026–  
706 3038.

707 Breitsprecher, D., and B.L. Goode. 2013. Formins at a glance. *J. Cell Sci.* 126:1–7.

708 Breitsprecher, D., A.K. Kiesewetter, J. Linkner, M. Vinzenz, T.E.B. Stradal, J.V. Small, U. Curth,  
709 R.B. Dickinson, and J. Faix. 2011. Molecular mechanism of Ena/VASP-mediated actin-  
710 filament elongation. *EMBO J.* 30:456–467.

711 Breitsprecher, D., K. Kiesewetter, J. Linkner, C. Urbanke, G.P. Resch, J.V. Small, J. Faix, A.K.  
712 Kiesewetter, J. Linkner, C. Urbanke, G.P. Resch, J.V. Small, and J. Faix. 2008. Clustering of  
713 VASP actively drives processive, WH2 domain-mediated actin filament elongation. *EMBO*  
714 *J.* 27:2943–2954.

715 Brühmann, S., D.S. Ushakov, M. Winterhoff, R.B. Dickinson, U. Curth, and J. Faix. 2017. Distinct  
716 VASP tetramers synergize in the processive elongation of individual actin filaments from  
717 clustered arrays. *PNAS.* 114:E5815–E5824.

718 Brzeska, H., J. Gonzalez, E.D. Korn, and M.A. Titus. 2020. Basic-hydrophobic sites are localized

- 719 in conserved positions inside and outside of PH domains and affect localization of  
720 *Dictyostelium* myosin 1s. *Mol. Biol. Cell.* 31:101–117.
- 721 Cao, R., J. Chen, X. Zhang, Y. Zhai, X. Qing, W. Xing, L. Zhang, Y.S. Malik, H. Yu, and X. Zhu.  
722 2014. Elevated expression of myosin X in tumours contributes to breast cancer  
723 aggressiveness and metastasis. *Br. J. Cancer.* 111:539–550.
- 724 Cavalier-Smith, T., and E.E.Y. Chao. 2003. Phylogeny and classification of phylum Cercozoa  
725 (Protozoa). *Protist.* 154:341–358.
- 726 Cheng, K.W., and R.D. Mullins. 2020. Initiation and disassembly of filopodia tip complexes  
727 containing VASP and lamellipodin. *Mol. Biol. Cell.* 1–39.
- 728 Cooper, J.A. 1987. Effects of cytochalasin and phalloidin on actin. *J. Cell Biol.* 105:1473–8.
- 729 Coué, M., S.L. Brenner, I. Spector, and E.D. Korn. 1987. Inhibition of actin polymerization by  
730 latrunculin A. *FEBS Lett.* 213:316–318.
- 731 Damiano-Guercio, J., L. Kurzawa, J. Mueller, G. Dimchev, M. Nemethova, S. Bruehmann, J.  
732 Linkner, L. Blanchoin, M. Sixt, K. Rottner, and J. Faix. 2020. Loss of Ena/VASP interferes  
733 with lamellipodium architecture, motility and integrin-dependent adhesion. *Elife.* 9:e55351.
- 734 Faix, J., D. Breitsprecher, T.E.B. Stradal, and K. Rottner. 2009. Filopodia: Complex models for  
735 simple rods. *Int. J. Biochem. Cell Biol.* 41:1656–1664.
- 736 Faix, J., and K. Rottner. 2006. The making of filopodia. *Curr. Opin. Cell Biol.* 18:18–25.
- 737 Friedman, A.L., M.A. Geeves, D.J. Manstein, and J.A. Spudich. 1998. Kinetic characterization of  
738 myosin head fragments with long-lived myosin·ATP states. *Biochemistry.* 37:9679–9687.
- 739 Gallop, J.L. 2020. Filopodia and their links with membrane traffic and cell adhesion. *Semin. Cell*  
740 *Dev. Biol.* 102:81–89.
- 741 Gerisch, G., T. Bretschneider, A. Müller-Taubenberger, E. Simmeth, M. Ecke, S. Diez, and K.  
742 Anderson. 2004. Mobile actin clusters and traveling waves in cells recovering from actin  
743 depolymerization. *Biophys. J.* 87:3493–3503.
- 744 Hamada, K. 2000. Structural basis of the membrane-targeting and unmasking mechanisms of  
745 the radixin FERM domain. *EMBO J.* 19:4449–4462.
- 746 Han, Y.H., C.Y. Chung, D. Wessels, S. Stephens, M.A. Titus, D.R. Soll, and R.A. Firtel. 2002.  
747 Requirement of a vasodilator-stimulated phosphoprotein family member for cell adhesion,  
748 the formation of filopodia, and chemotaxis in *Dictyostelium*. *J. Biol. Chem.* 277:49877–49887.
- 749 Hanousková, P., P. Táborský, and I. Čepička. 2019. *Dactylomonas* gen. nov., a novel lineage of  
750 Heterolobosean flagellates with unique ultrastructure, closely related to the amoeba  
751 *Seleniaion koniopes* Park, De Jonckheere & Simpson, 2012. *J. Eukaryot. Microbiol.* 66:120–139.
- 752 Hansen, S.D., and R.D. Mullins. 2010. VASP is a processive actin polymerase that requires  
753 monomeric actin for barbed end association. *J. Cell Biol.* 191:571–584.

- 754 Heckman, C.A., and H.K. Plummer. 2013. Filopodia as sensors. *Cell. Signal.* 25:2298–2311.
- 755 Heissler, S.M., and J.R. Sellers. 2016. Various themes of myosin regulation. *J Mol Biol.* 428:1927–  
756 1946.
- 757 Hess, S., N. Sausen, and M. Melkonian. 2012. Shedding light on vampires: The phylogeny of  
758 vampyrellid amoebae revisited. *PLoS One.* 7:e31165.
- 759 Hirao, M., N. Sato, T. Kondo, S. Yonemura, M. Monden, T. Sasaki, Y. Takai, S. Tsukita, and S.  
760 Tsukita. 1996. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma  
761 membrane association: Possible involvement of phosphatidylinositol turnover and rho-  
762 dependent signaling pathway. *J. Cell Biol.* 135:37–51.
- 763 Houdusse, A., and H.L. Sweeney. 2016. How myosin generates force on actin filaments. *Trends*  
764 *Biochem. Sci.* 41:989–997.
- 765 Humbel, B.M., and E. Biegelmann. 1992. A preparation protocol for postembedding  
766 immunoelectron microscopy of *Dictyostellium discoideum* cells with monoclonal antibodies.  
767 *Scanning Microsc.* 6:817–825.
- 768 Jasnin, M., F. Beck, M. Ecke, Y. Fukuda, A. Martinez-Sanchez, W. Baumeister, and G. Gerisch.  
769 2019. The architecture of traveling actin waves revealed by cryo-electron tomography.  
770 *Structure.* 27:1211-1223.e5.
- 771 Jung, G., C.J. Alexander, X.S. Wu, G. Piszczek, B.-C. Chen, E. Betzig, and J.A. Hammer. 2016. V-  
772 1 regulates capping protein activity in vivo. *Proc. Natl. Acad. Sci.* 113:E6610–E6619.
- 773 Kerber, M.L., D.T. Jacobs, L. Campagnola, B.D. Dunn, T. Yin, A.D. Sousa, O.A. Quintero, and  
774 R.E. Cheney. 2009. A novel form of motility in filopodia revealed by imaging myosin-X at  
775 the single-molecule level. *Curr. Biol.* 19:967–973.
- 776 Kollmar, M., and S. Mühlhausen. 2017. Myosin repertoire expansion coincides with eukaryotic  
777 diversification in the Mesoproterozoic era. *BMC Evol. Biol.* 17:211.
- 778 Lammers, M., R. Rose, A. Scrima, and A. Wittinghofer. 2005. The regulation of mDia1 by  
779 autoinhibition and its release by Rho•GTP. *EMBO J.* 24:4176–4187.
- 780 Lin, W.-H., J.T. Hurley, A.N. Raines, R.E. Cheney, and D.J. Webb. 2013. Myosin X and its  
781 motorless isoform differentially modulate dendritic spine development by regulating  
782 trafficking and retention of vasodilator-stimulated phosphoprotein. *J. Cell Sci.* 126:4756–68.
- 783 Liu, R., N. Billington, Y. Yang, C. Bond, A. Hong, V. Siththanandan, Y. Takagi, and J.R. Sellers.  
784 2021. A binding protein regulates myosin-7a dimerization and actin bundle assembly. *Nat.*  
785 *Commun.* 12:1–12.
- 786 Lu, Q., F. Ye, Z. Wei, Z. Wen, and M. Zhang. 2012. Antiparallel coiled-coil-mediated  
787 dimerization of myosin X. *Proc. Natl. Acad. Sci.* 109:17388–17393.
- 788 Masters, T.A., and F. Buss. 2017. Filopodia formation and endosome clustering induced by  
789 mutant plus-end-directed myosin VI. *Proc. Natl. Acad. Sci.* 114:1595–1600.

- 790 Mattila, P.K., and P. Lappalainen. 2008. Filopodia: molecular architecture and cellular functions.  
791 *Nat. Rev. Mol. Cell Biol.* 9:446–454.
- 792 Mattila, P.K., A. Pykäläinen, J. Saarikangas, V.O. Paavilainen, H. Vihinen, E. Jokitalo, and P.  
793 Lappalainen. 2007. Missing-in-metastasis and IRSp53 deform PI(4,5)P2-rich membranes by  
794 an inverse BAR domain-like mechanism. *J. Cell Biol.* 176:953–964.
- 795 Medalia, O., M. Beck, M. Ecke, I. Weber, R. Neujahr, W. Baumeister, and G. Gerisch. 2007.  
796 Organization of actin networks in intact filopodia. *Curr. Biol.* 17:79–84.
- 797 Mellor, H. 2010. The role of formins in filopodia formation. *Biochim. Biophys. Acta - Mol. Cell Res.*  
798 1803:191–200.
- 799 Merino, F., S. Pospich, J. Funk, T. Wagner, F. Küllmer, H.D. Arndt, P. Bieling, and S. Raunser.  
800 2018. Structural transitions of F-actin upon ATP hydrolysis at near-atomic resolution  
801 revealed by cryo-EM. *Nat. Struct. Mol. Biol.* 25:528–537.
- 802 Mogilner, A., and B. Rubinstein. 2005. The physics of filopodial protrusion. *Biophys. J.* 89:782–  
803 795.
- 804 Neujahr, R., R. Albrecht, J. Köhler, M. Matzner, J.M. Schwartz, M. Westphal, and G. Gerisch.  
805 1998. Microtubule-mediated centrosome motility and the positioning of cleavage furrows  
806 in multinucleate myosin II-null cells. *J. Cell Sci.* 111:1227–1240.
- 807 Nobes, C.D., and A. Hall. 1995. Rho, Rac, and Cdc42 GTPases regulate the assembly of  
808 multimolecular focal complexes associated with actin stress fibers, lamellipodia, and  
809 filopodia. *Cell.* 81:53–62.
- 810 Nolen, B.J., N. Tomasevic, A. Russell, D.W. Pierce, Z. Jia, C.D. McCormick, J. Hartman, R.  
811 Sakowicz, and T.D. Pollard. 2009. Characterization of two classes of small molecule  
812 inhibitors of Arp2/3 complex. *Nature.* 460:1031–1034.
- 813 Notredame, C., D.G. Higgins, and J. Heringa. 2000. T-coffee: A novel method for fast and  
814 accurate multiple sequence alignment. *J. Mol. Biol.* 302:205–217.
- 815 Novak, K.D., M.D. Peterson, M.C. Reedy, and M.A. Titus. 1995. *Dictyostelium* myosin I double  
816 mutants exhibit conditional defects in pinocytosis. *J. Cell Biol.* 131:1205–1221.
- 817 Parent, C.A., B.J. Blacklock, W.M. Froehlich, D.B. Murphy, and P.N. Devreotes. 1998. G protein  
818 signaling events are activated at the leading edge of chemotactic cells. *Cell.* 95:81–91.
- 819 Parra-Acero, H., N. Ros-Rocher, A. Perez-Posada, A. Kożyczkowska, N. Sánchez-Pons, A.  
820 Nakata, H. Suga, S.R. Najle, and I. Ruiz-Trillo. 2018. Transfection of *Capsaspora owczarzaki*, a  
821 close unicellular relative of animals. *Dev.* 145:1–8.
- 822 Pellegrin, S., and H. Mellor. 2005. The Rho family GTPase Rif induces filopodia through mDia2.  
823 *Curr. Biol.* 15:129–133.
- 824 Petersen, K.J., H.V. Goodson, A.L. Arthur, G.W.G. Luxton, A. Houdusse, and M.A. Titus. 2016.  
825 MyTH4-FERM myosins have an ancient and conserved role in filopod formation. *Proc.*

- 826 *Natl. Acad. Sci.* 113:E8059–E8068.
- 827 Planelles-Herrero, V.J., F. Blanc, S. Sirigu, H. Sirkia, J. Clause, Y. Sourigues, D. Johnsrud, B.  
828 Amigues, M. Cecchini, S.P. Gilbert, A. Houdusse, and M. Titus. 2016. Myosin MyTH4-  
829 FERM structures highlight important principles of convergent evolution. *Proc. Natl. Acad.*  
830 *Sci.* E2906–E2915.
- 831 Ropars, V., Z. Yang, T. Isabet, F. Blanc, K. Zhou, T. Lin, X. Liu, P. Hissier, F.F. Samazan, B.B.  
832 Amigues, E.D. Yang, H. Park, O. Pylypenko, M. Cecchini, C. V. Sindelar, H.L. Sweeney,  
833 and A. Houdusse. 2016. The myosin X motor is optimized for movement on actin bundles.  
834 *Nat. Commun.* 7:12456.
- 835 Sakai, T., N. Umeki, R. Ikebe, and M. Ikebe. 2011. Cargo binding activates myosin VIIA motor  
836 function in cells. *Proc. Natl. Acad. Sci. U. S. A.* 108:7028–7033.
- 837 Sasaki, N., R. Ohkura, and K. Sutoh. 2003. *Dictyostelium* myosin II mutations that uncouple the  
838 converter swing and ATP hydrolysis cycle. *Biochemistry.* 42:90–95.
- 839 Schirenbeck, A., R. Arasada, T. Bretschneider, T.E.B. Stradal, M. Schleicher, and J. Faix. 2006.  
840 The bundling activity of vasodilator-stimulated phosphoprotein is required for filopodium  
841 formation. *Proc. Natl. Acad. Sci.* 103:7694–7699.
- 842 Schirenbeck, A., T. Bretschneider, R. Arasada, M. Schleicher, and J. Faix. 2005. The Diaphanous-  
843 related formin dDia2 is required for the formation and maintenance of filopodia. *Nat. Cell*  
844 *Biol.* 7:619–625.
- 845 Sebé-Pedrós, A., P. Burkhardt, N. Sánchez-Pons, S.R. Fairclough, B.F. Lang, N. King, and I.  
846 Ruiz-Trillo. 2013. Insights into the origin of metazoan filopodia and microvilli. *Mol. Biol.*  
847 *Evol.* 30:2013–2023.
- 848 Shaner, N.C., M.Z. Lin, M.R. McKeown, P.A. Steinbach, K.L. Hazelwood, M.W. Davidson, and  
849 R.Y. Tsien. 2008. Improving the photostability of bright monomeric orange and red  
850 fluorescent proteins. *Nat. Methods.* 5:545–551.
- 851 Shibue, T., M.W. Brooks, M. Fatih Inan, F. Reinhardt, and R.A. Weinberg. 2012. The outgrowth  
852 of micrometastases is enabled by the formation of filopodium-like protrusions. *Cancer*  
853 *Discov.* 2:706–721.
- 854 Sousa, A.D., and R.E. Cheney. 2005. Myosin-X: A molecular motor at the cell's fingertips. *Trends*  
855 *Cell Biol.* 15:533–539.
- 856 Svitkina, T.M., E.A. Bulanova, O.Y. Chaga, D.M. Vignjevic, S. Kojima, J.M. Vasiliev, and G.G.  
857 Borisy. 2003. Mechanism of filopodia initiation by reorganization of a dendritic network. *J.*  
858 *Cell Biol.* 160:409–421.
- 859 Titus, M.A. 1999. A class VII unconventional myosin is required for phagocytosis. *Curr. Biol.*  
860 9:1297–1303.
- 861 Tokuo, H., and M. Ikebe. 2004. Myosin X transports Mena/VASP to the tip of filopodia. *Biochem.*



- 862 *Biophys. Res. Commun.* 319:214–220.
- 863 Tokuo, H., K. Mabuchi, and M. Ikebe. 2007. The motor activity of myosin-X promotes actin fiber  
864 convergence at the cell periphery to initiate filopodia formation. *J. Cell Biol.* 179:229–238.
- 865 Toyoshima, F., and E. Nishida. 2007. Integrin-mediated adhesion orients the spindle parallel to  
866 the substratum in an EB1- and myosin X-dependent manner. *EMBO J.* 26:1487–1498.
- 867 Tuxworth, R.I., S. Stephens, Z.C. Ryan, and M.A. Titus. 2005. Identification of a myosin VII-talin  
868 complex. *J. Biol. Chem.* 280:26557–26564.
- 869 Tuxworth, R.I., I. Weber, D. Wessels, G.C. Addicks, D.R. Soll, G. Gerisch, and M.A. Titus. 2001.  
870 A role for myosin VII in dynamic cell adhesion. *Curr. Biol.* 11:318–329.
- 871 Umeki, N., H.S. Jung, T. Sakai, O. Sato, R. Ikebe, and M. Ikebe. 2011. Phospholipid-dependent  
872 regulation of the motor activity of myosin X. *Nat. Struct. Mol. Biol.* 18:783–788.
- 873 Veltman, D.M., G. Akar, L. Bosgraaf, and P.J.M. Van Haastert. 2009. A new set of small,  
874 extrachromosomal expression vectors for *Dictyostelium discoideum*. *Plasmid.* 61:110–118.
- 875 Wallar, B.J., B.N. Stropich, J.A. Schoenherr, H.A. Holman, S.M. Kitchen, and A.S. Alberts. 2006.  
876 The basic region of the diaphanous-autoregulatory domain (DAD) is required for  
877 autoregulatory interactions with the diaphanous-related formin inhibitory domain. *J. Biol.*  
878 *Chem.* 281:4300–4307.
- 879 Weber, K.L., A.M. Sokac, J.S. Berg, R.E. Cheney, and W.M. Bement. 2004. A microtubule-  
880 binding myosin required for nuclear anchoring and spindle assembly. *Nature.* 431:325–329.
- 881 Weck, M.L., N.E. Grega-Larson, and M.J. Tyska. 2017. MyTH4-FERM myosins in the assembly  
882 and maintenance of actin-based protrusions. *Curr. Opin. Cell Biol.* 44:68–78.
- 883 Weeks, G., A.F. Lima, and T. Pawson. 1987. A RAS-encoded protein in *Dictyostelium discoideum*  
884 is acylated and membrane-associated. *Mol. Microbiol.* 1:347–354.
- 885 Westphal, M., A. Jungbluth, M. Heidecker, B. Mühlbauer, C. Heizer, J.M. Schwartz, G. Marriott,  
886 and G. Gerisch. 1997. Microfilament dynamics during cell movement and chemotaxis  
887 monitored using a GFP-actin fusion protein. *Curr. Biol.*
- 888 Yabuki, A., K.I. Ishida, and T. Cavalier-Smith. 2013. Fine structure of *Telonema subtilis*  
889 *Griessmann*, 1913: A flagellate with a unique cytoskeletal structure among Eukaryotes.  
890 *Protist.* 164:75–88.
- 891 Yang, C., L. Czech, S. Gerboth, S.I. Kojima, G. Scita, and T. Svitkina. 2007. Novel roles of formin  
892 mDia2 in lamellipodia and filopodia formation in motile cells. *PLoS Biol.* 5:2624–2645.
- 893 Yang, C., and T. Svitkina. 2011. Filopodia initiation: Focus on the Arp2/3 complex and formins.  
894 *Cell Adhes. Migr.* 5:402–408.
- 895 Yang, Y., T.G. Baboolal, V. Siththanandan, M. Chen, M.L. Walker, P.J. Knight, M. Peckham, and  
896 J.R. Sellers. 2009. A FERM domain autoregulates *Drosophila* myosin 7a activity. *Proc. Natl.*

- 897 *Acad. Sci. U. S. A.* 106:4189–4194.
- 898 Yang, Y., M. Kovacs, T. Sakamoto, F. Zhang, D.P. Kiehart, and J.R. Sellers. 2006. Dimerized  
899 *Drosophila* myosin VIIa: A processive motor. *Proc. Natl. Acad. Sci.* 103:5746–5751.
- 900 Young, L.E., C.J. Latario, and H.N. Higgs. 2018. Roles for Ena/VASP proteins in FMNL3-  
901 mediated filopodial assembly. 131.
- 902 Zhang, H., J.S. Berg, Y. Wang, P. Lång, A.D. Sousa, A. Bhaskar, R.E. Cheney, and S. Strömblad.  
903 2004. Myosin-X provides a motor-based link between integrins and the cytoskeleton. *Nat.*  
904 *Cell Biol.* 6:523–531.
- 905 Zhu, X.J., C.Z. Wang, P.G. Dai, Y. Xie, N.N. Song, Y. Liu, Q.S. Du, L. Mei, Y.Q. Ding, and W.C.  
906 Xiong. 2007. Myosin X regulates netrin receptors and functions in axonal path-finding. *Nat.*  
907 *Cell Biol.* 9:184–192.
- 908 Zonderland, J., P. Wieringa, and L. Moroni. 2019. A quantitative method to analyse F-actin  
909 distribution in cells. *MethodsX.* 6:2562–2569.
- 910
- 911

## 912 **Figure Legends**

913

914 **Figure 1. DdMyo7 has a distinct cortical localization from its tail domain.** **A.** (left) Schematic  
915 of DdMyo7 illustrating its motor domain (grey), 4 IQ domains (yellow) and tandem MyTH4-  
916 FERM domains (blue-MyTH4, red-FERM) in the tail, the tail fragment, and a motor forced  
917 dimer (motor-FD); (right) *Dictyostelium* control, or *myo7* null cells visualized with DIC and the  
918 membrane dye FM4-64 showing DdMyo7 is critical for filopodia formation. **B.** Confocal images  
919 showing localization of DdMyo7-mCherry at the cortex and in filopodia tips, and GFP-tail  
920 fragment localized around cortex. **C.** Line intensity profile along the line shown in panel B. **D.**  
921 Cytofluorograms comparing the colocalization between DdMyo7-mCherry (x-axis) and GFP-  
922 DdMyo7 or GFP-DdMyo7 tail (y-axis) **E.** Analysis strategy for measuring entire cell peripheral  
923 intensity. **F.** Micrographs of cells expressing RFP-LifeAct, GFP-DdMyo7, GFP-Tail, or GFP-  
924 Motor-Forced Dimer (FD). **A-F** Scale bars are 10 $\mu$ m. **G.** Peripheral line scan intensity of cells  
925 from F. **H.** Sample cortical band intensity showing the mean and variation of intensities around  
926 the periphery. **I.** Cortical band standard deviation (SD; n>93 cells from 3 experiments for each  
927 group). A higher SD indicates asymmetric localization. One-way ANOVA with multiple  
928 comparison correct compared to actin, \*\*\*\* p<0.001, ns not significant.

929

930 **Supplemental Figure 1. A.** Micrographs of control (AX2), *myo7* null or *myo7* null with GFP-  
931 DdMyo7 rescue construct expressing RFP-LifeAct (actin, top) and by GFP-DdMyo7 (bottom). **B.**  
932 Micrographs of cells co-expressing either GFP-DdMyo7 and DdMyo7-mCherry or GFP-  
933 DdMyo7-tail and DdMyo7-mCherry. Scale bars: 10 $\mu$ m.

934

935 **Figure 2. Actin dynamics regulate DdMyo7 recruitment to the cortex.** **A.** *Dictyostelium* co-  
936 expressing GFP-DdMyo7 and RFP-Lifeact. **B.** Line intensity profile from yellow dotted line in A  
937 (circle=beginning, arrowhead indicates end of scan). **C.** Cytofluorogram showing the  
938 colocalization of actin and DdMyo7, r is correlation coefficient. **D.** Confocal image series of an  
939 extending pseudopod. **E.** Normalized linescan intensity profile of DdMyo7 and actin in  
940 extending pseudopod along line from panel D. **F.** Intensity correlation of GFP-DdMyo7 and  
941 RFP-LifeAct plotted as the average spline fit of 10 extending pseudopodia. **G.** Confocal  
942 micrographs of cells expressing GFP-DdMyo7 (top) or RFP-LifeAct (actin, bottom) under noted  
943 drug condition. **A,D,G.** Scale bar is 10 $\mu$ m. **H.** Cortex:cytoplasm ratio (cortex is 0.8 $\mu$ m band of  
944 cell periphery) of GFP-DdMyo7 of cells treated with anti-actin drugs, circles are experimental  
945 means. One-way ANOVA with multiple comparison correction, shown to 1% DMSO control,  
946 \*\*p<0.01, p\*\*\*\*<0.0001.

947

948 **Supplemental Figure 2. A.** Micrographs of cells expressing DdMyo7 and GFP-CRAC (top) or  
949 GFP-tubulin (bottom) under noted drug condition. **B.** Quantification of additional  
950 pharmacological compounds on DdMyo7 cortical recruitment, cells were incubated with  
951 Ly294002 (Ly), Wortmannin (WM) or nocodazole (Noco). Circles are experimental means, one-  
952 way ANOVA indicates no data are significantly different from control. Scale bar is 10 $\mu$ m.

953

954 **Figure 3. VASP is required for DdMyo7 cortical recruitment.** **A.** Confocal images of wild type  
955 or *myo7* null, *vasp* null or *dia2* null cells expressing RFP-LifeAct (actin). **B.** Violin plot of number  
956 of filopodia per cell. **C.** Micrographs of cells expressing GFP-DdMyo7 (top) or GFP-VASP in  
957 *myo7* null, *vasp* null or *dDia2* null cells. **D.** Quantification of the cortical band (0.8 $\mu$ m of  
958 periphery) relative to the cytoplasmic intensity of either GFP-Myo7 or GFP-VASP. **A,C** Scale bar  
959 is 10 $\mu$ m. **B, D,** One-way ANOVA with multiple comparison correction, ns, not significant,  
960  $p^{***}<0.001$ , circles are experimental means.

961

962 **Supplemental Figure 3. Immunoprecipitation of DdMyo7.** **A.** GFP-DdMyo7 or GFP-  
963 DdMyo7-KKAA (see Fig 5) were immunoprecipitated from a clarified lysate (post nuclear spin  
964 sup; PNS) using anti-GFP beads. The PNS and immunoprecipitate pellet (IP Pell) were probed  
965 by western blot for DdMyo7, actin and DdVASP.

966

967 **Figure 4. Linear actin polymerization drives DdMyo7 to the cortex.** **A.** Images series showing  
968 DdMyo7 is absent from LatrunculinA-induced actin waves in control (top) or *vasp* null (bottom)  
969 cells. **B.** (top) Confocal images of GFP-DdMyo7 in *vasp* null cells treated with either DMSO or  
970 50nM Jasp treatment. (bottom) Images of cells expressing DdMyo7 and different actin  
971 modulating proteins. **C, D.** Average actin intensity (phalloidin staining, top) of cells through the  
972 longest cell axis. The line is the mean and the shaded area is the SEM (graphs, bottom). **A-D,**  
973 Scale bar is 10 $\mu$ m. **E.** Quantification of the cortical band intensity of DdMyo7 in *vasp* null cells,  
974 with no treatment, treated with Jasp, or also overexpressing V-1, *dia2*, or *dia2*-CA. **F.** Violin  
975 plot of filopodia per cell. **E-F.** One-way ANOVA with multiple comparison correction, ns, not  
976 significant, \*  $p<0.05$ , \*  $p^{****}<0.0001$ .

977

978 **Supplemental Figure 4. A.** Phalloidin staining of *vasp* null cells treated with either DMSO or  
979 50nM Jasplakinolide (Jasp). **B.** Quantification of induction of filopodia formation by control  
980 cells (no V1 OE) or cells that overexpress GFP-V1. Students t-test,  $^{***}p<0.001$ . **C.** Clustal Omega  
981 alignment of diaphanous related formins, conserved basic residues in the Dia autoregulatory  
982 domain (DAD) highlighted in yellow.

983

984 **Figure 5. Reduced cortical recruitment of DdMyo7 by VASP mutants.** **A.** Schematic of  
985 domains of DdVASP (top) and proposed interaction of DdVASP wildtype, monomeric, and F-  
986 actin binding (FAB K-E) mutant with actin filaments. **B.** Quantification of the cortical  
987 recruitment of DdMyo7 co-expressed in the *vasp* null with wildtype or mutant DdVASP rescue  
988 constructs. **C.** Quantification of filopodia per cell of *vasp* null cells with wildtype or mutant  
989 DdVASP rescue constructs. **B-C.** Circles represent experimental means. One-way ANOVA  
990 with multiple comparison correction,  $p^{****}<0.0001$ , ns not significant. **D.** Clustal Omega  
991 alignment of *Dictyostelium* and human VASP with conserved domains highlighted and mutated  
992 residues starred. **E.** Micrographs of GFP-DdMyo7 in *vasp* nulls, or *vasp* nulls expressing  
993 wildtype DdVASP or mutant DdVASP rescue constructs. Scale bar is 10 $\mu$ m.

994

995 **Figure 6. VASP relieves DdMyo7 head-tail autoinhibition to promote targeting and filopodia**  
996 **formation.** **A.** (top) Diagrams depicting mutants analyzed. (bottom) Micrographs of GFP-

997 DdMyo7 fusion proteins in control and *vasp* null cells, scale bar is 10 $\mu$ m **B.** Quantification of  
998 cortical recruitment of GFP-DdMyo7 and variants in *vasp* cells. The line represents the mean  
999 GFP-DdMyo7 recruitment in wild type cells. **C.** Comparison of cortical targeting of activated  
1000 KKAA or tail in *vasp* null versus control cells. **D.** Quantification of number of filopodia per cell  
1001 in control or *vasp* null cells. **B-D.** Circles represent experimental means. One way ANOVA with  
1002 multiple comparison test, ns not significant,  $p^{***}<0.001$ ,  $p^{****}<0.0001$ , ns, not significant. **E.**  
1003 Quantification of the cortical band intensity variation of DdMyo7-KKAA in control versus *vasp*  
1004 null cells. Students t-test  $****p<0.0001$ .

1005  
1006 **Figure 7. DdMyo7 motor activity is required to release autoinhibition.** **A.** Schematic of  
1007 proposed effect of mutations on DdMyo7 function. **B.** Confocal images of *myo7* null cells  
1008 expressing GFP-DdMyo7 fusion proteins, scale bar is 10 $\mu$ m. **C.** Quantification of the cortical  
1009 band intensity variation. Mean lines from Figure 1I data on graph for comparison. DdMyo7  
1010 versus I426A uncoupler,  $p^{**}<0.01$ . **D.** Fraction of DdMyo7 cosedimenting with the cytoskeleton,  
1011 symbols with the same shape are technical replicates, students t-test  $****p<0.0001$ . **E.**  
1012 Quantification of cortical recruitment of DdMyo7 and mutants. **F.** Filopodia number per cell of  
1013 wildtype and mutant DdMyo7. **E-F.** Data for KKAA is taken from Figure 6, experimental  
1014 means shown as circles. **C, E, and F,** One-way ANOVA with multiple comparison correction  
1015 , $p^{***}<0.001$ ,  $p^{****}<0.0001$ , ns not significant.

1016  
1017 **Supplemental Figure 5. Conservation of the DdMyo7 motor domain.** **A.** M-coffee sequence  
1018 alignment (Wallace et al., 2006) of the relay helix region of different myosin motor domains, left  
1019 column number is amino acid position. Switch 2 and L50 subdomain are shaded, circled  
1020 columns indicate the highly conserved glutamic acid in switch 2 (non-hydrolyzer, DdMyo7  
1021 E386V) and hydrophobic residue in relay loop (uncoupler, DdMyo7 I426A). Symbols below  
1022 indicate degree of conservation between sequences: '\*' identical, ':' strongly similar, '.' weakly  
1023 similar. **B.** Western blot analysis of two cytoskeleton prep supernatants (S) and pellets (P) from  
1024 *myo7* null cells expressing either wildtype or the E386V mutant. Band at 270kDa is DdMyo7,  
1025 band at 42kDa is actin.

1026  
1027 **Figure 8. Model of DdMyo7 and VASP mediated filopodia initiation.** **A.** The leading edge of  
1028 the cell has a branched actin network. **B.** VASP polymerizes actin at the leading edge,  
1029 organizing the filaments into linear, parallel bundles. **C.** Autoinhibited DdMyo7 is activated  
1030 and the motor domain binds to actin within the VASP-actin network. **D.** Cooperative actions of  
1031 VASP (bundles and polymerizes) and DdMyo7 dimers (bundle) organized actin filaments into  
1032 nascent filopodia that continue to elongate by actin polymerization. **E.** Proposed model of  
1033 DdMyo7 motor activation by actin. (left) depiction of the conformation change when the myosin  
1034 is activated by relief of head-tail autoinhibition. (right) depiction of activated DdMyo7 binding  
1035 actin via its motor domain, followed by dimerization and bundling of actin, generating force to  
1036 bring actin filaments together. If the motor encounters a VASP actin network, it can dimerize  
1037 and generate force, but if not, then it cycles back to an off state.

1038

1039 **Supplemental Figure 6.** Whole cell lysates from each line were analyzed for expression of  
1040 endogenous proteins or expressed fusion proteins. The blot was also probed for the 125 kD  
1041 MyoB heavy chain, the loading control. Antibodies used to probe each set of blots are indicated  
1042 below and the molecular weights in kD marked on the side. **A.** Control wild type (WT, Ax2),  
1043 *myo7* null or *vasp* null cell lines. Note that DdVASP runs at ~ 50 kD, higher than its calculated  
1044 molecular weight of ~ 40 kD. **B.** GFP-DdMyo7 expression in control (WT, Ax3) and *vasp* null  
1045 cells, and GFP-VASP in control wild type (Ax2) and *myo7* null cells. **C.** Expression of wild type  
1046 or mutant GFP-DdMyo7 in *myo7* null cells. Note that GFP-DdVASP runs at ~ 75 kD, higher  
1047 than its calculated molecular weight of ~ 65 kD **D.** Expression of wild type VASP and VASP  
1048 mutants (not fused to a fluorescent protein) in *vasp* null cells. **E.** Wild type, *vasp* null and *vasp*  
1049 null cell line overexpressing GFP-dDia2 CA. **F.** Western blot of GFP-V1 induced (+Dox) in  
1050 control (Ax3) cells.  
1051

1052 **Table 1.**  
 1053 **Cortical recruitment ratio of DdMyo7 and filopodia per cell for GFP-DdMyo7/*myo7* null cells**  
 1054 **treated with various pharmacological compounds.**  
 1055

	Buffer Only	1% DMSO	
percent of cells with filopodia	42	38	
filopodia number + SEM	2.01±0.11	1.97±0.09	
cortex:cytoplasm ratio + SEM	1.18±0.01	1.2±0.02	
N, n	4, 238	3, 229	
	1µM cytochalasinA	5µM cytochalasinA	30µM cytochalasinA
percent of cells with filopodia	0	8.5	19
filopodia number + SEM	0	1.3±0.04	0.1 ±0.06
cortex:cytoplasm ratio + SEM	1.02±0.02	1.07±0.01	1.04±0.02
N, n	3, 66	3, 234	1, 42
	1µM latrunculinA	5µM latrunculinA	15µM latrunculinA
percent of cells with filopodia	19	4.7	20
filopodia number + SEM	1.73±0.06	1.33±0.05	0.24±0.06
cortex:cytoplasm ratio + SEM	1.12±0.01	1.02±0.01	1.08 ± 0.02
N, n	4, 387	3, 127	1, 74
	15nM Jasplakinolide	50nM Jasplakinolide	100nM Jasplakinolide
percent of cells with filopodia	55	72	48
filopodia number + SEM	1.47±0.23	3.89±0.2	2.21±0.09
cortex:cytoplasm ratio + SEM	1.19±0.03	1.34±0.03	1.24±0.02
N, n	1,84	3, 219	3, 337
	20µM Ly294002	60µM Ly294002	2µM Wortmannin
percent of cells with filopodia	22	40	30
filopodia number + SEM	0.56±0.44	0.87±0.12	0.84±0.16
cortex:cytoplasm ratio + SEM	1.22±0.08	1.17±0.04	1.16±0.02
N, n	2,9	4,194	2,101
	15µM Nocodazole	50µM Nocodazole	25µM CK666
percent of cells with filopodia	n.c	47.3	10.7
filopodia number + SEM	n.c	1.64±0.13	0.145±0.03
cortex:cytoplasm ratio + SEM	1.25±0.02	1.19±0.02	1.12±0.01
N, n	1,97	4, 169	3,366

1056

1057

1058

1059

**Table 2.**  
**Quantification of filopodia number and cortical targeting.**

	GFP- DdMyo7	GFP- KCAA	GFP- DdMyo7- E386V	GFP- DdMyo7- E386V- KCAA	GFP- DdMyo7- I426A	GFP- DdMyo7- CAAX	GFP- DdMyo7- Tail	GFP- VASP				
myo7-	percent of cells with filopodia	49	80	1	3	22	58	n.c.	n.c.			
	filopodia number + SEM	2.29±0.15	5.32±0.33	1±0	1.5±0.09	1.75±0.15	2.87±0.14	n.c.	n.c.			
	cortex:cytoplasm ratio + SEM	1.14±0.02	1.67±0.06	1±0.01	1.32±0.04	1.19±0.04	1.39±0.03	1.61±0.07	1.18±0.29			
	N, n	3, 158	3, 133	3, 186	3, 59	3, 37	3, 237	3, 55	3, 91			
vasp-	GFP- DdMyo7	GFP- DdMyo7; VASP- 1M	GFP- DdMyo7; VASP - WT	GFP- DdMyo7; VASP- FAB-K-E	GFP- VASP	GFP- DdMyo7- CAAX	GFP- DdMyo7- Tail	GFP- DdMyo7- KCAA	mCherry- Dia2	mCherry- Dia2-CA	GFP-V1	
	percent of cells with filopodia	7	35	69	14	n.c.	4	n.c.	4	0	29	0
	filopodia number + SEM	1.25±0.07	3.78±0.31	3.07±0.25	1.39±0.03	n.c.	1.2±0.03	n.c.	1±0	0±0	2.03±0.24	0±0
	cortex:cytoplasm ratio + SEM	1.06±0.01	1.2±0.02	1.47±0.05	1.19±0.01	1.18±0.33	1.24±0.01	1.35±0.02	1.29±0.02	1.65±0.03	1.82±0.09	1.12±0.02
N, n	3, 118	3, 131	3, 81	3, 322	3, 200	4, 239	3, 213	3, 193	5,447	8,94	3,35	




	GFP- DdMyo7	GFP- DdMyo7- CAAX	GFP- DdMyo7- Tail	GFP- DdMyo7- KKAA	GFP- VASP		
Ax2 control							
percent of cells with filopodia	45	54	n.c.	73	n.c.		
filopodia number + SEM	2.36±0.2	2.9±0.15	n.c.	3.65±0.2	n.c.		
cortex:cytoplasm ratio + SEM	1.35±0.03	1.45±0.04	1.41±0.02	1.79±0.07	1.16±0.25		
N, n	4, 124	5, 266	4, 351	3, 219	4, 216		

1060

1061 Average number of filopodia per cells from cells with at least one filopodia. Cortex:cytoplasm ratio is intensity ratio of a 0.8µm band  
 1062 around the periphery compared to the cytoplasm. N is number of experiments, n is number of cells. SEM is standard error of the  
 1063 mean. GFP-VASP and GFP-DdMyo7-Tail fail to efficiently target to filopodia tip and were not counted in this analysis.


# Figure 1

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




# Supplemental Figure 1

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




# Figure 2

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




# Supplemental Figure 2

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




# Figure 3

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




# Supplemental Figure 3

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.



# Figure 4


bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.





# Supplemental Figure 4

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




**C**

Q54N00 FORH_Dd	1013	PEKGGQLQLSSQIRSGQLFKD	RR	VGDSVIAQMQN-----VDSLKRN
O70566.2 DIAP2_Mm	1047	DETVMDNLLEALQSGAAFRD	RRKR	I PRNPDNRRPP---LERSR--
O60879.1 DIAP2_Hs	1050	DETVMDNLLEALQSGAAFRD	RRKR	I PRNPDNRRVP---LERSR--
P41832.3 BNI1_Sc	1795	DRRAVMDKLLQLKNAGPAKSDPSSA	RKR	ALVRKKYLSEKDNAPQL
P48608.2 DIA_Dm	1023	TQEGVMDLLEALQTGSAFGQRNRQA	RRQR	PAGAERRAQLSRSRSR


# Figure 5

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




# Figure 6

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.



# Figure 7

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.



# Supplemental Figure 5


bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

**A**

		switch 2	relay helix / relay loop	L50 subdomain
DdMyo5	488	GFESFEVNGFEQFCINYANEK	LQQLFNQHVFKKEEQEYIKER	IDWSYIDFN
DdMyo7	384	GFENFKKNSFEQFCINFANEK	LQQHFNQHIFKLEQEEYEKER	INWSKIVYN
DdMyo2	457	GFEIFKVNSFEQLCINYTNEK	LQQFFNHHMFKLEQEEYLKER	INWTFIDFG
ScMyo2	451	GFEHFEKNSFEQFCINYANEK	LQQEFNQHVFVKLEQEEYVKEE	IEWSFIEFN
XlMyo5	442	GFETFEINSFEQFCINYANEK	LQQQFNLHVFKLEQEEYMKEQ	IPWTLIDFY
DmMYO7A	434	GFENFDQNSFEQFCINYANEN	LQQFFVQHIFKLEQEEYNHEA	INWQHIEFV
HsMYO10	437	GFENFEVNHFEQFNINYANEK	LQEQYFNKHIFSLEQLEYSREGL	VWEDIDWI
HsMYO7A	440	GFENFAVNSFEQLCINFANEH	LQQFFVRHVFKLEQEEYDLES	IDWLHIEFT
HsMYO7B	440	GFENFENNSFEQLCINFANEH	LQQFFVQHVFTMEQEEYRSENI	SWDYIHYT
		*** * * ***: **::**:**: * *:* . ** ** * : * * :		


*non-hydrolyzable* (pointing to switch 2 region)

*uncoupler* (pointing to L50 subdomain region)



# Figure 8

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.435667>; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.



# Supplemental Figure 6

